<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD004201.pub2" GROUP_ID="INCONT" ID="769903011715064611" MERGED_FROM="" MODIFIED="2012-07-11 22:08:09 +0100" MODIFIED_BY="Muhammad Imran Omar" NOTES="&lt;p&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.8&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.6&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-11 22:05:33 +0100" NOTES_MODIFIED_BY="Muhammad Imran Omar" REVIEW_NO="" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="6.0">
<COVER_SHEET MODIFIED="2012-07-11 22:08:09 +0100" MODIFIED_BY="Muhammad Imran Omar">
<TITLE>Urinary catheter policies for long-term bladder drainage</TITLE>
<CONTACT MODIFIED="2012-07-11 22:08:09 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="DE3FED6482E26AA200F94DADE212D43E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Laercio</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Silva</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>lansilva@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Doutor Nicolau de Sousa Queiros, 629. Ap.130B</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04105002</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5573 1796</PHONE_1><FAX_1>+55 11 9976 4475</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-07-11 22:08:09 +0100" MODIFIED_BY="Muhammad Imran Omar"><PERSON ID="14249" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Barbara</FIRST_NAME><MIDDLE_INITIALS>S</MIDDLE_INITIALS><LAST_NAME>Niël-Weise</LAST_NAME><EMAIL_1>B.S.Niel-Weise@lumc.nl</EMAIL_1><ADDRESS><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><ADDRESS_2>C9-43</ADDRESS_2><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 526 6762</PHONE_1></ADDRESS></PERSON><PERSON ID="14270" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Peterhans</FIRST_NAME><MIDDLE_INITIALS>J</MIDDLE_INITIALS><LAST_NAME>van den Broek</LAST_NAME><EMAIL_1>P.J.van_den_Broek@lumc.nl</EMAIL_1><ADDRESS><DEPARTMENT>Department of Infectious Diseases</DEPARTMENT><ORGANISATION>Leiden University Medical Center</ORGANISATION><ADDRESS_1>PO Box 9600</ADDRESS_1><ADDRESS_2>C5-P</ADDRESS_2><CITY>Leiden</CITY><ZIP>2300 RC</ZIP><COUNTRY CODE="NL">Netherlands</COUNTRY><PHONE_1>+31 71 526 2290</PHONE_1></ADDRESS></PERSON><PERSON ID="94269467157500054890110922155833" ROLE="AUTHOR"><PREFIX>A/Prof</PREFIX><FIRST_NAME>Edina</FIRST_NAME><MIDDLE_INITIALS>MK</MIDDLE_INITIALS><LAST_NAME>da Silva</LAST_NAME><SUFFIX>MD, PhD</SUFFIX><POSITION>Associate Professor</POSITION><EMAIL_1>edinaksilva@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Emergency Medicine and Evidence Based Medicine, Brazilian Cochrane Centre</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Pedro de Toledo, 598</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04039001</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5575 2970</PHONE_1></ADDRESS></PERSON><PERSON ID="DE3FED6482E26AA200F94DADE212D43E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Laercio</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Silva</LAST_NAME><POSITION>Researcher</POSITION><EMAIL_1>lansilva@terra.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Department of Urology</DEPARTMENT><ORGANISATION>Universidade Federal de São Paulo</ORGANISATION><ADDRESS_1>Rua Doutor Nicolau de Sousa Queiros, 629. Ap.130B</ADDRESS_1><CITY>São Paulo</CITY><ZIP>04105002</ZIP><REGION>São Paulo</REGION><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 11 5573 1796</PHONE_1><FAX_1>+55 11 9976 4475</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-07-09 15:09:33 +0100" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="28" MONTH="9" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="28" MONTH="9" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="9" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2003"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2005"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2012-07-09 15:10:07 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2012-07-09 15:08:45 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Two new studies identified and one included in the review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-07-09 15:10:07 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="7" YEAR="2012"/>
<DESCRIPTION>
<P>Two new studies identified and one included in the review. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2012-07-09 15:07:42 +0100" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-07-09 15:07:42 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="3" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Minor update, no new studies. Twelve new studies identified from Incontinence register; all were excluded.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-08-03 11:43:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="13" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-10-28 14:57:27 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="10" MONTH="5" YEAR="2006"/>
<DESCRIPTION>
<P>first update</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="17" MONTH="11" YEAR="2004"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Health Service Research and Development Programme</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-07-09 17:37:27 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-28 15:27:50 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-28 15:27:50 +0000" MODIFIED_BY="[Empty name]">Urinary catheter policies for long-term bladder drainage</TITLE>
<SUMMARY_BODY>
<P>Some people use catheters to help them manage their bladder problems (such as leaking urine or not being able to pass urine). Catheters may be permanent urethral catheters (in the tube draining the bladder), suprapubic catheters (via the abdomen) or intermittent catheters (when a catheter is inserted via the urethra several times a day). No trials were found comparing these different methods with each other. Sometimes people using the catheters develop urinary tract infections. There was some weak evidence that using antibiotics all the time reduced the chance of having a urinary tract infection while using intermittent catheters, but there was not enough information about side effects. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-07-09 15:16:11 +0100" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>People requiring long-term bladder draining commonly experience catheter-associated urinary tract infection and other problems.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine if certain catheter policies are better than others in terms of effectiveness, complications, quality of life and cost-effectiveness in long-term catheterised adults and children.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-06-04 12:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Incontinence Group Specialised Trials Register (searched 28 September 2011). Additionally, we examined all reference lists of identified trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised and quasi-randomised trials comparing catheter policies (route of insertion and use of antibiotics) for long-term (more than 14 days) catheterisation in adults and children. </P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-07-09 15:15:47 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Data were extracted by two reviewers independently and compared. Disagreements were resolved by discussion. Data were processed as described in the Cochrane Handbook. If the data in trials had not been fully reported, clarification was sought from the authors. When necessary, the incidence-density rates (IDR) and/or the incidence-density differences (IDD) within a certain time period were calculated.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-07-09 15:15:57 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials met the inclusion criteria involving 504 patients in four cross-over and four parallel-group randomised controlled trials. Only two of the pre-stated six comparisons were addressed in these trials.<BR/>
<BR/>Four trials compared antibiotic prophylaxis with antibiotics when clinically indicated. For patients using intermittent catheterisation, there were inconsistent findings about the effect of antibiotic prophylaxis on symptomatic urinary tract infection (UTI). Only one study found a significant difference in the frequency of UTI favouring prophylaxis. For patients using indwelling urethral catheterisation, one small trial reported fewer episodes of symptomatic UTI in the prophylaxis group.</P>
<P>Four trials compared antibiotic prophylaxis with giving antibiotics when microbiologically indicated. For patients using intermittent catheterisation, there was limited evidence that receiving antibiotics reduced the rate of bacteriuria (asymptomatic and symptomatic). There was weak evidence that prophylactic antibiotics were better in terms of fewer symptomatic bacteriuria.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-09 15:16:11 +0100" MODIFIED_BY="[Empty name]">
<P>No eligible trials were identified that compared alternative routes of catheter insertion. The data from eight trials comparing different antibiotic policies were sparse, particularly when intermittent catheterisation was considered separately from indwelling catheterisation. Possible benefits of antibiotic prophylaxis must be balanced against possible adverse effects, such as development of antibiotic resistant bacteria. These cannot be reliably estimated from currently available trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-07-09 17:37:27 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2012-07-09 15:20:45 +0100" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2012-07-09 15:17:24 +0100" MODIFIED_BY="[Empty name]">
<P>Long-term catheterisation of the bladder is most commonly used in the care of frail, elderly people in nursing homes or as part of their home care. In Canada, about 5% to 10% of residents of long-term care facilities have chronic indwelling catheters for weeks, months or years (<LINK REF="REF-Nicolle-2001" TYPE="REFERENCE">Nicolle 2001</LINK>). However, younger patients with neurological disease or spinal injury may also use catheters in the long term. The bladder performs two main functions, storage and emptying. The indications for catheterisation are failure to store and/or failure to empty, particularly urinary incontinence and urinary retention. In view of the ageing population in many countries, the number of people exposed to the risks of long-term indwelling catheterisation may increase, although the proportion of people whose urinary problems can only be managed by catheterisation may decrease because of improvements in other treatments for urinary incontinence and conditions which cause it.<BR/>
<BR/>Catheter-associated urinary tract infection represents the most common infection acquired in long-term facilities (<LINK REF="REF-Warren-1994" TYPE="REFERENCE">Warren 1994</LINK>). The incidence of bacteria in the urine (bacteriuria) has been estimated to be about 3% to 10% higher each day after catheter insertion (<LINK REF="REF-Warren-1982a" TYPE="REFERENCE">Warren 1982a</LINK>). Therefore, after one month of catheterisation almost all patients would be expected to be bacteriuric. As in short-term catheterisation, asymptomatic bacteriuria can be complicated by the effects of symptomatic infection, e.g. fever, acute pyelonephritis and bacteraemia. Long-term catheterisation is also associated with catheter obstruction, urinary tract stones, local infections, chronic renal inflammation, renal failure and, over years, bladder cancer (<LINK REF="REF-Warren-1997" TYPE="REFERENCE">Warren 1997</LINK>).<BR/>
<BR/>Bacteria get into the catheterised bladder by direct inoculation at the time of catheter insertion or via the following routes during catheterisation: extraluminally by ascending from the urethral meatus along the catheter urethral interface, and intraluminally by reflux of the organisms into the catheter lumen (<LINK REF="REF-Tambyah-1999" TYPE="REFERENCE">Tambyah 1999</LINK>; <LINK REF="REF-Warren-2001" TYPE="REFERENCE">Warren 2001</LINK>). Biofilm formation and encrustation on the catheter surface, in combination with a high prevalence of recurrent bacterial entry, result in a dynamic polymicrobial bacteriuria (<LINK REF="REF-Liedl-2001" TYPE="REFERENCE">Liedl 2001</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2012-07-09 15:20:33 +0100" MODIFIED_BY="[Empty name]">
<P>The first step in reducing catheter-associated urinary tract infections and other complications is to avoid unnecessary catheterisation; the second is to remove the catheter as soon as possible. Alternative methods to indwelling urethral catheterisation should be considered, such as intermittent catheterisation and suprapubic catheterisation. From a theoretical point of view, it is plausible that both these methods are associated with a decreased risk of local infections and complications, but this remains to be proven. </P>
<P>Once a catheter is in place, the aim is to minimise the risk of infection. There are two accepted basic principles: keeping the catheter system closed; and removing the catheter when it is no longer needed. A further strategy concerns antibiotic prophylaxis: it is widely accepted that receiving systemic antibiotics reduces the risk of catheter-associated urinary tract infection in the short-term catheterised patient (<LINK REF="REF-Huth-1992" TYPE="REFERENCE">Huth 1992</LINK>; <LINK REF="REF-Platt-1986" TYPE="REFERENCE">Platt 1986</LINK>; <LINK REF="REF-Shapiro-1984" TYPE="REFERENCE">Shapiro 1984</LINK>). If systemic antibiotics are also effective in the long-term catheterised patient, we need to find out whether the protective effect of prophylactic antibiotics (used continuously) counterbalances the side effects, particularly the emergence of bacterial resistance to multiple antibiotics. Possible strategies to reduce these disadvantages are limiting antibiotic use: a) to patients with a positive urine culture (usually set at a predefined density of bacteria), b) to those with clinical symptoms (such as pain or fever), or c) to certain circumstances such as when changing the catheter.</P>
</INTERVENTION>
<THEORY MODIFIED="2012-07-09 15:20:39 +0100" MODIFIED_BY="[Empty name]">
<P>With regard to intermittent catheterisation, i.e. inserting and removing a sterile or clean urethral catheter several times daily, micro-organisms are unlikely to gain entry into the bladder by ascending inside or along the outer surface of the catheter because the catheter is no longer constantly present. With respect to suprapubic catheterisation, bacterial colonisation of the urinary tract is less likely because of the lower density of (gram-negative) micro-organisms on the abdominal skin than in the periurethral area, although the catheter may still act as a route for infection. There are also disadvantages to these alternatives.</P>
</THEORY>
<IMPORTANCE MODIFIED="2012-07-09 15:20:45 +0100" MODIFIED_BY="[Empty name]">
<P>The first aim of this review is to address, in the context of long-term use, whether one of the catheter options (i.e. indwelling urethral catheterisation, intermittent urethral catheterisation or suprapubic catheterisation) is better than another in terms of suitability for the condition, complications, replacement, satisfaction (person with the problem, their carers and staff providing care) and cost-effectiveness. The second aim of this review is to assess the evidence from randomised controlled trials on the effectiveness of prophylactic (continuous) systemic (oral as opposed to local or topical) antibiotics, including which patient groups should receive antibiotics and in which circumstances, when a long period of catheterisation is anticipated.</P>
<P>Another strategy to reduce the incidence of problems in people who have long-term indwelling catheters is to wash out the bladder. However, this strategy was evaluated in another Cochrane review (<LINK REF="REF-Hagen-2010" TYPE="REFERENCE">Hagen 2010</LINK>). With respect to indwelling catheterisation (i.e. urethral or suprapubic), a further possible strategy to reduce the risk of infection is to use catheters coated with an antibacterial substance. The effect of using different types of urethral catheters in the short-term (up to 14 days) is evaluated in a Cochrane review that is in the process of being updated (<LINK REF="REF-Schumm-2008b" TYPE="REFERENCE">Schumm 2008b</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2012-07-09 15:20:52 +0100" MODIFIED_BY="Charlotte Archibald">
<P>To determine if certain catheter policies are better than others in terms of effectiveness, complications, quality of life and cost-effectiveness in long-term catheterised adults and children.<BR/>Specific comparisons to be addressed included:<BR/>1. indwelling urethral catheterisation compared with suprapubic catheterisation;<BR/>2. indwelling urethral catheterisation compared with intermittent catheterisation;<BR/>3. suprapubic catheterisation compared with intermittent catheterisation;<BR/>4. antibiotic prophylaxis compared with giving antibiotics when clinically indicated;<BR/>5. antibiotic prophylaxis compared with giving antibiotics when microbiologically indicated; and<BR/>6. giving antibiotics, if microbiologically indicated, compared with giving antibiotics if clinically indicated.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-07-09 17:37:27 +0100" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2012-07-09 15:22:27 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All randomised and quasi-randomised trials comparing catheter policies (route of insertion and use of antibiotics) for long-term catheterisation of the bladder in adults and children.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>All patients requiring long-term catheterisation for urinary incontinence or retention that cannot be managed by another method. This could include people suffering from stress, urge and mixed incontinence, dementia, prostatic hypertrophy unsuitable for other management, stroke, neurological problems, spinal cord injury and spina bifida. They may receive this care at home, in residential homes or in hospital. In this review, long term is defined as more than 14 days.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2011-12-19 12:09:14 +0000" MODIFIED_BY="[Empty name]">
<P>The interventions considered were:<BR/>1. continuous indwelling urethral, intermittent urethral, and suprapubic use of catheters; and<BR/>2. antibiotic prophylaxis (continuous use), use of antibiotics if clinically indicated (e.g. pain, fever) and use of antibiotics if microbiologically indicated (growth of bacteria from a specimen of urine in the absence of clinical symptoms).</P>
<P>Antibiotics were divided into two categories:<BR/>
</P>
<UL>
<LI>broad spectrum (active against a wide range of bacteria); and</LI>
<LI>narrow spectrum (active against certain types of bacteria only, usually prescribed when a culture of a urine sample has identified a particular bacterium shown to be sensitive to the antibiotic, or when only a limited range of bacteria of known sensitivity are likely to be present).</LI>
</UL>
<P>In addition, the routes of administration (oral or intravenous, but not local or topical) were considered.<BR/>
<BR/>The following interventions were not considered in the present review:<BR/>
</P>
<UL>
<LI>catheterisation insertion techniques (e.g. clean, sterile, with or without antiseptic or antibiotic cream);</LI>
<LI>meatal care management techniques (e.g. routine hygiene, antiseptic or antibiotic cream); and</LI>
<LI>management of drainage systems (e.g. use of sterile or clean drainage bags, use of antiseptic solutions, washout/irrigation of drainage bags).</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-07-09 15:22:27 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Subjective and objective measures:</HEADING>
<UL>
<LI>patient comfort;</LI>
<LI>patient satisfaction;</LI>
<LI>ease of use for patient;</LI>
<LI>sexual function;</LI>
<LI>incontinence/bypass leakage;</LI>
<LI>need to use supplementary pads/bed pads;</LI>
<LI>ease of use for practitioner;</LI>
<LI>need to change catheters;</LI>
<LI>number of catheters used;</LI>
<LI>length of time catheters used.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Complications/adverse effects:</HEADING>
<UL>
<LI>asymptomatic bacteriuria;</LI>
<LI>symptomatic urinary tract infections;</LI>
<LI>use of prophylactic antibiotics;</LI>
<LI>use of rescue antibiotics;</LI>
<LI>urethral strictures;</LI>
<LI>bladder stones;</LI>
<LI>urgency/bladder spasms/detrusor overactivity;</LI>
<LI>other adverse effects of intervention (other than urinary tract infection).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Quality of life:</HEADING>
<UL>
<LI>generic QoL measures (e.g. Short Form 36, <LINK REF="REF-Ware-1992" TYPE="REFERENCE">Ware 1992</LINK>);</LI>
<LI>psychological outcome measures (e.g. HADS, <LINK REF="REF-Zigmond-1983" TYPE="REFERENCE">Zigmond 1983</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Economic outcomes:</HEADING>
<UL>
<LI>costs of intervention(s);</LI>
<LI>resource implications of differences in outcomes;</LI>
<LI>formal economic analysis (cost-effectiveness, cost utility).</LI>
</UL>
<P>Any other non-prespecified outcomes judged to be important when performing the review.</P>
</SUBSECTION>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-07-03 20:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>We did not impose any language restriction or other limits on the searches.</P>
<ELECTRONIC_SEARCHES MODIFIED="2012-01-31 10:54:55 +0000" MODIFIED_BY="[Empty name]">
<P>This review has drawn on the search strategy developed for the Incontinence Group as a whole. Relevant trials have been primarily identified from the Cochrane Incontinence Group Specialised Trials Register. The methods used to derive this, including the search strategy, are described in the Group's <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/INCONT/frame.html">module</A> in <I>The Cochrane Library</I>. The register contains trials identified from MEDLINE, CINAHL and<I> </I>the Cochrane Central Register of Controlled Trials<I> </I>(CENTRAL) and handsearching of journals and conference proceedings.</P>
<P>The Incontinence Group Trials Register was searched using the Group's own keyword system. The search terms used were:</P>
<P>(design.rct* or design.cct*)<BR/>AND<BR/>({intvent.mech.cath*} or {intvent.mech.device*} or {intvent.mech.sheaths.} or {intvent.prevent.antibiotics*} or {intvent.prevent.antinfect.*} or {intvent.prevent.cath*} or {intvent.prevent.cleaning fluids*} or {intvent.prevent.surg*} or {intvent.surg.intraoperativemanagement*} or {intvent.surg.postsurgman*} or {intvent.surg.presurgman*.} or {intvent.surg.urethrotomy.})</P>
<P>(All searches were of the keyword field of Reference Manager 12, Thomson Reuters).<BR/>Date of the most recent search of the register for this review: 28 September 2011.<BR/>The trials in the Incontinence Group Specialised Register are also contained in CENTRAL.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-07-03 20:35:10 +0100" MODIFIED_BY="[Empty name]">
<P>Additionally, all reference lists of identified trials were searched.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-07-09 17:37:27 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2012-07-09 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>The reviewers independently assessed all titles and abstracts identified by the search. Where there was any possibility that the study could be included, the full paper was obtained. Any disagreement that could not be resolved by discussion was resolved by consultation with an independent third person.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-07-09 17:37:27 +0100" MODIFIED_BY="[Empty name]">
<P>Data were extracted by two reviewers independently and compared. If the data in trials were not fully reported, clarification was sought directly from the authors. Included trial data were processed as described in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). </P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-07-09 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>Two reviewers independently assessed each report for inclusion and methodological quality using the Cochrane Incontinence Group's quality assessment tool: disagreements were resolved through discussion with the third reviewer. The Group's checklist covered quality of random allocation and concealment, description of dropout and withdrawals, analysis by intention-to-treat, and 'blinding' during treatment and at outcome assessment.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-07-09 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>If the trialists did not pay attention to the time that patients were at risk, we calculated the incidence-density relative rates (IDR) and/or the incidence-density differences (IDD) and number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) within a certain period (<LINK REF="REF-Bouter-1995" TYPE="REFERENCE">Bouter 1995</LINK>). The incidence density was calculated using the following formula:<BR/>
</P>
<UL>
<LI>in the numerator: total number of events (bacteriuria or symptomatic urinary tract infection);</LI>
<LI>in the denominator: total person time of follow-up minus time not at risk (total number of events multiplied by the average number of days antibiotics were given plus total number of days receiving antibiotics for other reasons than event).</LI>
</UL>
<P>For categorical outcomes we related the numbers reporting an outcome to the numbers at risk in each group to derive a relative risk (RR) or to the total person time at risk (IDR). For continuous variables we used means and standard deviations to derive a weighted mean difference (WMD).</P>
<P>For cross-over trials, if data from the first arm of the trial were available, we analysed the data from the first period as if from a parallel-group trial and if the data had allowed, we would have combined results from both designs. If the data from the first arm of the trial were not available, the data were entered into Other Data Tables and comparisons were made only on the direction of any differences.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-07-09 15:24:02 +0100" MODIFIED_BY="[Empty name]">
<P>The unit of analysis was based on the individual patient (unit to be randomised for interventions to be compared).</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-07-09 15:24:21 +0100" MODIFIED_BY="[Empty name]">
<P>Irrespective of the type of data, we reported dropout rates in the '<LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>' table.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-07-09 15:24:26 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were compared to assess and investigate the likelihood of important clinical heterogeneity. This also took into account the results of the Chi<SUP>2</SUP> test for heterogeneity. As a general rule, the outcome data were combined using a fixed-effect model to calculate pooled estimates and their 95% confidence intervals. However, a random-effects model was considered where there were concerns that heterogeneity could be complicating an analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-07-09 15:24:31 +0100" MODIFIED_BY="[Empty name]">
<P>When appropriate, meta-analyses were undertaken. We performed statistical analyses according to the statistical guidelines referenced in the <I>Cochrane Handbook for Systematic Reviews of Interventions </I>(<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>).<I> </I>
</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-06-06 20:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Trials were subgrouped by whether the catheterisation was intermittent or indwelling. </P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-07-09 15:24:36 +0100" MODIFIED_BY="[Empty name]">
<P>If the data had allowed, we would have performed sensitivity analyses to assess the impact of trial quality, such as adequate versus poor allocation concealment but such data were not reported. Similarly, if the data had allowed, we would have performed subgroup analyses for different diagnostic groups or according to the sex of participants but such data were not reported.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-07-09 15:27:15 +0100" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2012-07-09 15:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>The literature search produced a total of 624 records which were screened for this review. The flow of literature through the assessment process is shown in the PRISMA flowchart (
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>
).</P>
<SEARCH_RESULTS MODIFIED="2012-07-09 15:24:43 +0100" MODIFIED_BY="[Empty name]">
<P>Seven trials were included in the first version of the review (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>
<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>
<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK> <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>
<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK> <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). Four were cross-over trials (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>;<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>;, <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>) and three were parallel-group randomised controlled trials (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK> <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>). One further trial was included in this update (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-07-09 15:25:30 +0100" MODIFIED_BY="[Empty name]">
<P>Eight trials were included in this review (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>; <LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>). Details are given in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.</P>
<UL>
<LI>Four were cross-over trials (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>).</LI>
<LI>Four were parallel-group randomised controlled trials (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>; <LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>Four trials involved adult patients with neurogenic bladder of differing types, all of whom were using intermittent catheterisation:</P>
<UL>
<LI>Two parallel-group trials included hospitalised adults with acute neurogenic bladder following recent spinal cord injury who were using intermittent self-catheterisation (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). In one of these trials, only male patients were included (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>); in the other trial, almost seven times more males were included, but the distribution of men and women was equal between the trial groups (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>).</LI>
<LI>One other parallel-group trial also involved adult hospitalised patients who were using intermittent catheterisation for neurogenic bladder, but it was not clear whether the neurogenic bladder was an acute problem or longstanding (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>). In that trial, three times more males were included, but the trial groups were comparable with regard to sex.</LI>
</UL>
<UL>
<LI>One cross-over trial included mainly male volunteers with neurogenic bladder using intermittent self-catheterisation at home (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>); the reasons why patients suffered from neurogenic bladder were not reported.</LI>
</UL>
<UL>
<LI>One other cross-over trial included elderly nursing home inpatients with long-term urethral catheters (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>). In that trial, indications for catheterisation were various.</LI>
</UL>
<P>Three trials involved children:</P>
<UL>
<LI>Two cross-over trials included children with neurogenic bladder due to meningomyelocele who were using intermittent self-catheterisation at home (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). In one of these trials, neurogenic bladder was due to spinal cord injury (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). Both trials involved more girls than boys.</LI>
</UL>
<UL>
<LI>In a randomised controlled trial with parallel groups only, children with neurogenic bladder due to spina bifida and clean intermittent catheterisation were studied, with more girls than boys (57% versus 43%) (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Duration of catheterisation</HEADING>
<P>In the four cross-over trials, all patients were catheterised for longer than 14 days. In three trials, patients were catheterised for 12 weeks (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>), and in one trial for 20 weeks (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). In the included parallel-group RCTs, the duration of catheterisation was not the same for all patients. In one trial, patients were catheterised for a mean of nine weeks, ranging from one to 16 weeks (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). In the other two trials, the longest patients were catheterised was until hospital discharge (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>); the mean duration was not reported for either of these trials. In one parallel-group RCT the follow-up was 18 months (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Types of intervention</HEADING>
<P>All included trials, except two (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>), randomised participants to prophylactic antibiotics or a matching placebo. Of the two remaining trials, in one (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>) patients in the control group were openly allocated to no prophylaxis, and in the other trial (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>) the participants were openly randomised to continuation or discontinuation of low dose prophylaxis.<BR/>
<BR/>Three different types of antibiotics were investigated:</P>
<UL>
<LI>nitrofurantoin (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>);</LI>
<LI>trimethoprim-sulphamethoxazole (TMX-SMX) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>); and</LI>
<LI>norfloxacin (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</LI>
</UL>
<P>With regard to the papers studying the effect of nitrofurantoin, patients in one trial (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>) received twice as much nitrofurantoin as did patients in another trial (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>). In two trials (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>), similar approaches were used to adjust the dose of medication depending on children's weights. In the trials of TMX-SMX prophylaxis, the dose was four times higher in one (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) than in the other (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). In one study, patients assigned to continuation of prophylactic antibiotic used various schemes in low doses, which included trimethoprim, nitrofurantoin, cefuroxime, co-trimoxazole or a combination of prophylactics (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcome measures</HEADING>
<P>The definition of significant bacteriuria ranged from 10<SUP>2</SUP> colony forming units per ml to greater than 10<SUP>5</SUP> colony forming units per ml. The definition of symptomatic urinary tract infection did not always involve bacteriuria (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>).</P>
<P>Two trials reported adverse events (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>). In one (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>), adverse events were defined as side effects due to trial medication; in the other (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>), the definition incorporated both adverse events due to trial medication and catheter-related complications (i.e. obstruction, encrustation, leakage, suprapubic pain, inflammation of meatus, and haematuria).</P>
<P>To detect trial medication-resistant organisms, the Kirby-Bauer disk diffusion method was used in two trials (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</P>
<P>Only one trial evaluated patients' general condition by the assessment of: 'well-being' of the patient; appreciation of his or her social involvement; awareness; need for nursing care; and functional status (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-07-09 15:25:38 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies were excluded (<LINK REF="STD-Kuhlemeier-1985" TYPE="STUDY">Kuhlemeier 1985</LINK>; <LINK REF="STD-Maynard-1984" TYPE="STUDY">Maynard 1984</LINK>; <LINK REF="STD-Warren-1982b" TYPE="STUDY">Warren 1982b</LINK>). One did not address any of the questions posed in this review (<LINK REF="STD-Warren-1982b" TYPE="STUDY">Warren 1982b</LINK>), and the others did not have sufficient information to judge the study methods (<LINK REF="STD-Kuhlemeier-1985" TYPE="STUDY">Kuhlemeier 1985</LINK>) or extract outcome data (<LINK REF="STD-Maynard-1984" TYPE="STUDY">Maynard 1984</LINK>). Two comparisons in one other study were also excluded (<LINK REF="STD-Mohler-1987b" TYPE="STUDY">Mohler 1987b</LINK>). One other trial (<LINK REF="STD-Clarke-2005" TYPE="STUDY">Clarke 2005</LINK>) was excluded due to excessive losses after randomisations (38%) in unequal proportions between groups, which was considered to be high risk of attrition bias. The reasons for exclusion are listed in the table of <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
<P>A further 14 studies were excluded for a variety of other reasons (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-07-09 15:26:11 +0100" MODIFIED_BY="[Empty name]">
<P>Details of the quality of each trial are given in the table of <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<ALLOCATION MODIFIED="2012-07-09 15:25:49 +0100" MODIFIED_BY="[Empty name]">
<P>Not all trials described the group allocation method in detail. Two trials used an adequate method of concealment of allocation: in one trial (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>), authors applied block randomisation in groups of eight which was pre-stratified using two factors: the presence or absence of prior bacteriuria; and the participant's sex. The randomisation sequence was obtained from a separate computer-generated randomisation schedule. A randomisation 'table' was used in one trial (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>). If the authors stated that a trial was randomised, double blind and placebo-controlled, we have assumed that allocation to groups was adequately concealed, and classed this as an adequate allocation concealment. Four trials were described as such (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). Only in one trial was the method of allocation concealment unclear (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>). One study performed a computer based, random, concealed allocation, and only the outcome assessor was blind (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).<BR/>
</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-07-09 15:25:55 +0100" MODIFIED_BY="[Empty name]">
<P>The six trials with adequate randomisation were all placebo-controlled and hence clinical staff and patients were blind to the allocated intervention. Those testing urine samples were also blinded. Clinical staff and patients were not blinded in one trial (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>): the participants were openly allocated antibiotics or no antibiotics. The authors did not report whether the outcome assessor was blinded (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-07-09 15:26:00 +0100" MODIFIED_BY="[Empty name]">
<P>In three trials, none of the participants were lost after randomisation (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>), but in one, 38% of patients without prophylaxis switched to the prophylaxis group (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>) as the authors performed a treatment effect analyses according to the intention-to-treat principle; this study was not excluded. In another two trials, loss after randomisation was 2% (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) and 6% (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). In one trial (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>), more than 30% of the randomised patients did not complete the trial. The authors reported the numbers of patients lost and reasons why patients were lost according to allocation to treatment. There were no indications of selective loss. In another trial (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>) 35% of the randomised patients did not complete the trial and, in the last trial (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>), 15% of randomised children were lost after randomisation. We were unable to judge whether or not the losses differed between the trial groups.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-07-09 15:26:04 +0100" MODIFIED_BY="[Empty name]">
<P>We had no concerns about selective reporting since important clinical outcomes were evaluated.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-07-09 15:26:11 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Intention-to-treat analysis</HEADING>
<P>Intention-to-treat analysis was followed in seven of the trials. In one trial (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>), it was not clear whether this principle was followed.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Cross-over trials</HEADING>
<P>With regard to the four cross-over trials, there was a one-month washout period in one of these (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>); there was no washout period in the other three (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</P>
</SUBSECTION>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-07-09 15:27:15 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison 1: Indwelling urethral catheterisation compared with suprapubic catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 2: Indwelling urethral catheterisation compared with intermittent catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 3: Suprapubic catheterisation compared with intermittent catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 4: Antibiotic prophylaxis compared with giving antibiotics when clinically indicated</HEADING>
<P>Four eligible trials addressed this comparison (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>; <LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>). Three were cross-over trials and one was a parallel group controlled trial (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>). Two trials tested nitrofurantoin against placebo in children using intermittent catheterisation (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>); one trial tested norfloxacin against placebo in elderly patients using indwelling urethral catheterisation (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>). One trial enrolled children using intermittent catheterisation who were in use of different regimens of prophylaxis and randomised to continuation or discontinuation with follow-up of 18 months and outcome assessor blinded (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Bacteriuria (asymptomatic and symptomatic)</HEADING>
<P>Bacteriuria was not considered as an outcome measure in this review because asymptomatic bacteriuria was not treated and, therefore, it was not a useful measure in this setting.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic urinary tract infection (UTI)</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Participants with trials of intermittent catheterisation</HEADING>
<P>For two trials we calculated the rate of symptomatic UTI per catheterisation week (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>; <LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). In a trial involving 15 children, those receiving prophylactic antibiotics ran almost half of the risk for UTI, but this was not statistically significant (IDR 0.50, 95% CI 0.17 to 1.44, <LINK REF="CMP-004.01" TYPE="ANALYSIS">Analysis 4.1</LINK>.1 (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). Of the 15 participants, eight had at least one UTI while taking prophylactic antibiotics compared with 11 when taking placebo (<LINK REF="CMP-004.03" TYPE="ANALYSIS">Analysis 4.3</LINK>.1) (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>). In the bigger trial (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>), there were four cases of UTI in 430 catheterised weeks during antibiotic prophylaxis compared with two cases in 389 control weeks without antibiotics (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.1) (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>). In spite of being clinically and methodologically homogeneous, the two trials thus showed inconsistent results for symptomatic UTI.</P>
<P>In the third trial (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>), those who continued taking prophylaxis had fewer episodes of at least one febrile symptomatic UTI, but this was not statistically significant (RR 0.50, 95% CI 0.09 to 2.66) (<LINK REF="CMP-004.10" TYPE="ANALYSIS">Analysis 4.10</LINK>.1) ). However, the antibiotic prophylaxis group did have significantly fewer afebrile symptomatic UTIs (IDR 0.69, 95% CI 0.55 to 0.87) (<LINK REF="CMP-004.11" TYPE="ANALYSIS">Analysis 4.11</LINK>.1), with number needed to treat for an additional harmful outcome of 2.2. </P>
<P>It was not possible to perform meta-analysis of the three trials due heterogeneity in the method of classification of UTI and outcome measures.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Trials of indwelling urethral catheterisation</HEADING>
<P>In the open trial of prophylaxis amongst patients with an indwelling catheter, there were fewer symptomatic UTIs during antibiotic prophylaxis than during control periods without antibiotics (one in 276 catheterisation weeks versus 12 in 259 weeks) (<LINK REF="CMP-004.02" TYPE="ANALYSIS">Analysis 4.2</LINK>.2)) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Participants with intermittent catheterisation</HEADING>
<P>No data on other outcomes were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Participants with indwelling urethral catheterisation</HEADING>
<P>Other outcome measures were reported only for the single trial of patients with indwelling urethral catheters. In this trial, the results in the antibiotic group were better in terms of:</P>
<UL>
<LI>rate of visual encrustation per catheterisation week (<LINK REF="CMP-004.04" TYPE="ANALYSIS">Analysis 4.4</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>),</LI>
<LI>rate of catheter-obstructions (<LINK REF="CMP-004.05" TYPE="ANALYSIS">Analysis 4.5</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>),</LI>
<LI>rate of adverse events (<LINK REF="CMP-004.06" TYPE="ANALYSIS">Analysis 4.6</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>),</LI>
<LI>number of patients with improved general condition (<LINK REF="CMP-004.07" TYPE="ANALYSIS">Analysis 4.7</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>) and</LI>
<LI>number of gram-negative isolates (<LINK REF="CMP-004.09" TYPE="ANALYSIS">Analysis 4.9</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</LI>
</UL>
<P>However, for the outcome 'percentage of resistant strains', the results were in favour of the control group (<LINK REF="CMP-004.08" TYPE="ANALYSIS">Analysis 4.8</LINK>) (<LINK REF="STD-Rutschmann-1995" TYPE="STUDY">Rutschmann 1995</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 5: Antibiotic prophylaxis compared with giving antibiotics when microbiologically indicated</HEADING>
<P>Four eligible trials were found (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>). Three were parallel-group randomised controlled trials (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) and one was a cross-over trial (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>). The trial populations were all adult patients using intermittent catheterisation. One trial (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>) tested nitrofurantoin against no nitrofurantoin; another trial (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>) tested nitrofurantoin against placebo and two trials tested TMP-SMX against placebo (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>).</P>
<SUBSECTION>
<HEADING LEVEL="4">Asymptomatic bacteriuria</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Participants with intermittent catheterisation</HEADING>
<P>All four trials provided data on bacteriuria. For three trials we were able to calculate the rate of bacteriuria per catheterisation week (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>). In one trial (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>), this was not possible; the authors of that trial presented the outcome as having at least one episode of bacteriuria.</P>
<P>The two parallel-group trials found that patients in the prophylactic antibiotic group had fewer episodes of bacteriuria than patients not receiving prophylactic antibiotics (IDR of the pooled analysis 0.61, 95% CI 0.44 to 0.87, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.1; IDD -0.14, 95% CI -0.23 to -0.05, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>) (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) although there was evidence of heterogeneity. The results of the cross-over trial were also in favour of the prophylaxis group (<LINK REF="CMP-005.02" TYPE="ANALYSIS">Analysis 5.2</LINK>) (<LINK REF="STD-Duffy-1982" TYPE="STUDY">Duffy 1982</LINK>). Anderson (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>) also analysed the effect according to the frequency of catheterisation and found some evidence that the effect of prophylaxis was greater in the subgroup who used intermittent catheterisation every four hours rather than every eight hours (every four hours: IDR 0.15, 95% CI 0.05 to 0.42, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.2; every eight hours: IDR 0.49, 95% CI 0.21 to 1.12, <LINK REF="CMP-005.01" TYPE="ANALYSIS">Analysis 5.1</LINK>.3) (<LINK REF="STD-Anderson-1980" TYPE="STUDY">Anderson 1980</LINK>).</P>
<P>Gribble (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>) found that although there were fewer patients having at least one episode of bacteriuria in the antibiotic group, this did not quite reach statistical significance (RR 0.86, 95% CI 0.72 to 1.02, <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>.1) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). The authors reported the effect separately for men and women and found similar RRs (for males: RR 0.85, 95% CI 0.71 to 1.03, <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>.2; for females: RR 0.89, 95% CI 0.57 to 1.38, <LINK REF="CMP-005.07" TYPE="ANALYSIS">Analysis 5.7</LINK>.3) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Participants with indwelling urethral catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Symptomatic bacteriuria</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Participants with intermittent catheterisation</HEADING>
<P>Two trials (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>; <LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) reported data on symptomatic bacteriuria. For one trial (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>) we calculated the rate of symptomatic bacteriuria per catheterisation week. The results showed that patients in the prophylactic antibiotic group had a lower rate than patients not receiving prophylactic antibiotics but this was not statistically significant (IDR 0.56, 95% CI 0.27 to 1.15, <LINK REF="CMP-005.05" TYPE="ANALYSIS">Analysis 5.5</LINK>) (<LINK REF="STD-Mohler-1987a" TYPE="STUDY">Mohler 1987a</LINK>).</P>
<P>In the other trial, fewer patients in the prophylactic antibiotic group had at least one episode of symptomatic bacteriuria, and this was statistically significant (RR 0.19, 95% CI 0.07 to 0.53, <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>.1; RD -0.26, 95% CI -0.39 to -0.13, <LINK REF="CMP-005.09" TYPE="ANALYSIS">Analysis 5.9</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). Most participants were male and all except one of the episodes was in a man (<LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>.2 and <LINK REF="CMP-005.08" TYPE="ANALYSIS">Analysis 5.8</LINK>.3) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Participants with indwelling urethral catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Other outcome measures</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">a) Participants with intermittent catheterisation</HEADING>
<P>Other outcome measures were reported for only one trial (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). We calculated the rate of adverse events per catheterisation week. The results were better in the antibiotic group but were not statistically significant (IDR 0.74, 95% CI 0.53 to 1.02, <LINK REF="CMP-005.06" TYPE="ANALYSIS">Analysis 5.6</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). There was also no statistically significant difference in the number of patients having at least one episode of adverse events (RR 0.86, 95% CI 0.64 to 1.14, <LINK REF="CMP-005.10" TYPE="ANALYSIS">Analysis 5.10</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). Fewer patients in the prophylaxis group were prescribed antibiotics for at least one episode of urinary tract infection (RR 0.78, 95% CI 0.62 to 0.97, <LINK REF="CMP-005.11" TYPE="ANALYSIS">Analysis 5.11</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>). There were also few data about possible antibiotic resistance. Although there were no differences in: at least one episode of bacteriuria due to TMX-SMX-resistant organisms (RR 0.95, 95% CI 0.77 to 1.17, <LINK REF="CMP-005.12" TYPE="ANALYSIS">Analysis 5.12</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>); and, at least one time recovery of TMX-SMX-resistant gram-negative bacilli from weekly surveillance cultures (RR 1.17, 95% CI 0.80 to 1.72, <LINK REF="CMP-005.13" TYPE="ANALYSIS">Analysis 5.13</LINK>) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>), the confidence intervals were all wide.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">b) Participants with indwelling urethral catheterisation</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison 6: Giving antibiotics, if microbiologically indicated, compared with giving antibiotics if clinically indicated</HEADING>
<P>No eligible trials were found.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-07-09 15:28:25 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;i&gt;&lt;span class=&quot;marker&quot;&gt;XX I am not clear what the difference is between febrile and afebrile UTI&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-06 19:11:46 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;The authors of the trial reported&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:12:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:12:02 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;results&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:11:46 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; separately for children with clinical symptoms of &lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:12:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;UTI&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:11:46 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; and urine&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:12:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; test&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:11:46 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; &lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:12:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;positive&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:11:46 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt; with or without fever reported.&lt;/span&gt;&lt;span modified=&quot;2012-06-06 19:13:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-06 19:13:00 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;i&gt;&lt;span class=&quot;marker&quot;&gt;XX is there something missing here?&lt;/span&gt;&lt;/i&gt;&lt;span modified=&quot;2012-06-06 19:13:50 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;(&lt;/span&gt;&lt;a link_type=&quot;STUDY&quot; href=&quot;Anderson 1980&quot; protected=&quot;true&quot;&gt;Anderson 1980&lt;/a&gt;&lt;span modified=&quot;2012-06-06 19:13:50 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;; &lt;/span&gt;&lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987a&quot; protected=&quot;true&quot;&gt;Mohler 1987a&lt;/a&gt;&lt;span modified=&quot;2012-06-06 19:13:50 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;)&lt;/span&gt;&lt;/p&gt;&lt;p&gt;&lt;span modified=&quot;2012-06-06 19:15:25 -0300&quot; modified_by=&quot;[Empty name]&quot; class=&quot;inserted&quot;&gt;This piece was part of the original review and was published as well. We removed these links.&lt;/span&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-07-09 15:28:25 +0100" NOTES_MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2012-07-09 15:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>This systematic review identified eight eligible trials that addressed two of the six pre-stated hypotheses. Only one of these was amongst frail, elderly patients; the others studied patients (adults or children) with neurogenic bladder problems using intermittent catheterisation. We found no trials that compared indwelling urethral catheterisation with suprapubic catheterisation, indwelling urethral catheterisation with intermittent catheterisation, suprapubic catheterisation with intermittent catheterisation, or giving antibiotics if microbiologically indicated with giving antibiotics if clinically indicated (Comparisons 1 to 3, or 6). Six out of the eight included trials of different antibiotic policies included patients using intermittent catheterisation, despite there being no RCT that establishes that intermittent catheterisation is the preferable policy. It would be clinically valuable to conduct trials to address the question whether one technique is superior to another.</P>
<P>We analysed whether antibiotic prophylaxis was better than giving antibiotics when clinically indicated (comparison 4); this included three cross-over trials that analysed a total of 94 catheterised patients (71 with intermittent catheterisation, 23 with indwelling urethral catheterisation) and one parallel group trial with 176 participants with intermittent catheterisation. Several types of antibiotics were tested: nitrofurantoin, norfloxacin, trimethoprim, cefuroxime, co-trimoxazole or a combination of prophylactics. All four trials used an adequate method of randomisation concealment and all four provided the outcome measure symptomatic UTI. Only one of the trials addressed other outcome measures, such as visual encrustation, catheter obstructions, adverse events, general condition, percentage of resistant strains and spectrum of microbial isolates. Therefore, there were few useful data for addressing concerns about possible adverse effects of antibiotic prophylaxis.</P>
<P>The results of the patients using intermittent catheterisation were kept separate from those of patients with indwelling urethral catheterisation; the pathway of getting bacteriuria is different and it is conceivable, therefore, that patients run different risks of infection. It is clinically important to know whether the effect of prophylactic antibiotics is concentrated in certain groups.</P>
<P>For patients using intermittent catheterisation, there was some inconsistency between the trials. In the two cross-over studies, there were no significant differences between groups, with fewer UTIs in the intervention group in one study (<LINK REF="STD-Schlager-1998" TYPE="STUDY">Schlager 1998</LINK>), and fewer UTIs in the control group in another study (<LINK REF="STD-Johnson-1994" TYPE="STUDY">Johnson 1994</LINK>). The additional trial included in the update of this review (<LINK REF="STD-Zegers-2011" TYPE="STUDY">Zegers 2011</LINK>) separated the classification of symptomatic UTI into febrile and afebrile, a method not used in previous studies. For febrile UTI there was no significant difference between the group with prophylactic antibiotics and control. However, afebrile UTI occurred significantly less frequently in the group with prophylactic antibiotics; the number needed to treat for an additional harmful outcome was 2.2.</P>
<P>For patients using indwelling urethral catheterisation, the one small trial suggested that prophylaxis reduced symptomatic UTI. This trial also favoured the prophylactic antibiotic group in respect of other outcomes, except for microbial resistance pattern. As expected, the trial suggested that an important disadvantageous effect of prophylactic antibiotics was the selection of antimicrobial-resistant micro-organisms.</P>
<P>We did not include bacteriuria (asymptomatic and symptomatic) as an outcome measure, because patients who had previously had untreated asymptomatic bacteriuria would run a greater risk of having a repeated positive urine culture. Thus, there was a strong interdependence of the various contributions of bacteriuria, which might have led to invalid results.</P>
<P>We also analysed if antibiotic prophylaxis is better than giving antibiotics when microbiologically indicated (comparison 5), and included three RCTs and one cross-over trial, involving a total of 234 patients using intermittent catheterisation. There were two types of antibiotics tested: nitrofurantoin and TMX-SMX. Three trials used an adequate method of randomisation concealment, one trial an inadequate method. All four trials provided the outcome measure bacteriuria (asymptomatic and symptomatic). Two trials addressed the outcome measure symptomatic bacteriuria and a single trial included the outcome measures adverse events, need of antibiotics for UTI, bacteriuria due to TMX-SMX-resistant organisms and recovery of TMX-SMX-resistant gram-negative bacilli.</P>
<P>The limited evidence available suggested that receiving prophylactic antibiotics reduced the rate of bacteriuria (asymptomatic and symptomatic). The results of the pooled incidence rate difference in bacteriuria (asymptomatic and symptomatic) suggested about 14 fewer periods of bacteriuria within two years when patients received prophylactic antibiotics (IDD -0.14, 95% CI -0.23 to -0.05, <LINK REF="CMP-005.03" TYPE="ANALYSIS">Analysis 5.3</LINK>). There was weak evidence that prophylactic antibiotics were better in terms of less symptomatic bacteriuria and less need for antibiotics for UTIs. There were no statistically significant differences in the effects on adverse events, bacteriuria due to TMX-SMX-resistant organisms and recovery of TMX-SMX-resistant gram-negative bacilli from weekly surveillance cultures, but confidence intervals were wide.</P>
<P>We could not calculate the risk difference in symptomatic bacteriuria for Gribble's study, because the follow-up of patients was so variable (mean time in the trial was nine weeks in both groups, with a range from one to 16 weeks) (<LINK REF="STD-Gribble-1993" TYPE="STUDY">Gribble 1993</LINK>).</P>
</SUMMARY_OF_RESULTS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-07-09 15:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>The quality of the trials and their reporting were generally unsatisfactory. All the included trials had small sample sizes and overall 504 patients were randomised. Therefore, estimates of differential effects were imprecise, with wide confidence intervals. Just two trials clearly had adequate concealment of randomisation although it was assumed in five others. Two trials did not report whether there were dropouts and in another two trials more than 30% of the randomised participants were lost. It was frustrating that the data from the cross-over trials were reported as if they were from a parallel group trial. As a results, we could not analyse them in MetaView as the appropriate statistics were not available. Given the nature of the intervention, the cross-over trials might have been expected to have a 'washout' period, but this occurred in only one trial. The possibilities for combining data were also limited by clinical heterogeneity.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-07-09 15:27:48 +0100" MODIFIED_BY="[Empty name]">
<P>The choice of measure of subsequent UTI is not straightforward. Most of the trials did not pay attention to the fact that, in the long-term catheterisation setting, trial participants could be infected more than once. Patients who had had bacteriuria or a clinical UTI were treated with systemic antibiotics. During a period of having bacteriuria or a clinical symptomatic UTI and receiving systemic antibiotics, patients were not at risk for the intended outcome measure. In addition, within the parallel-group RCTs, patients were followed over differing periods of time. We have attempted to obtain more valid results by transforming the data of most of the included trials using the methods of incidence density. However, this approach does not take into account possible 'clustering' of events in a few individuals; for this reason we have also reported (where available) the number of participants who ever had an infection.</P>
<P>Another concern is that it is conceivable that the effect of prophylactic antibiotics is different in patients learning the technique of intermittent catheterisation from patients who had mastered the technique. None of the trialists controlled for that in the analysis.</P>
<P>In summary, the clinically most relevant measure for infection is symptomatic UTI. The effect of prophylactic antibiotics on symptomatic UTI in the long-term setting can be measured by the rate of infection or by the number of patients having at least one infection. The rate of infection allows us to detect whether patients allocated to the prophylaxis group had fewer infections within a certain period. The number of patients having at least one episode of infection enables us to detect whether clinical infections are limited to certain patients. Future trials should pay more attention to these considerations.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2012-07-09 15:28:25 +0100" MODIFIED_BY="[Empty name]">
<P>Despite the relevance of the subject, so far, few studies of quality have evaluated the effectiveness and safety of various urinary catheter policies for long-term bladder drainage. This lack of evidence was also found in other systematic reviews. One that aimed to analyse the catheter policies for management of long-term voiding problems in adults with neurogenic bladder disorders, concluded that there have not been any randomised trials to provide good evidence (<LINK REF="REF-Jamison-2011" TYPE="REFERENCE">Jamison 2011</LINK>). Another review evaluated the long-term bladder management by intermittent catheterisation in adults and children, and concluded that it is not possible to state that one catheter type, technique or strategy is better than another due to insufficient quality trials (<LINK REF="REF-Moore-2007" TYPE="REFERENCE">Moore 2007</LINK>). Finally, a systematic review about types of indwelling urinary catheters for long-term bladder drainage in adults concluded that the evidence was not sufficient as a reliable basis for practical conclusions because all trials included were small and showed methodical weaknesses (<LINK REF="REF-Jahn-2007" TYPE="REFERENCE">Jahn 2007</LINK>).</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-07-09 15:28:47 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-07-09 15:28:38 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Is indwelling urethral catheterisation better than suprapubic catheterisation?</HEADING>
<P>No eligible trials were identified that addressed this question.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is indwelling urethral catheterisation better than intermittent catheterisation?</HEADING>
<P>No eligible trials were identified that addressed this question.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is suprapubic catheterisation better than intermittent catheterisation?</HEADING>
<P>No eligible trials were identified that addressed this question.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is antibiotic prophylaxis better than giving antibiotics when clinically indicated?</HEADING>
<P>The evidence available is not sufficient as a basis for determining practice. For patients using intermittent catheterisation the data were inconclusive with only one of three studies with statistically significant differences favouring prophylaxis. For patients using indwelling urethral catheterisation, only a single inconclusive cross-over trial investigated this issue.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is antibiotic prophylaxis better than giving antibiotics when microbiologically indicated?</HEADING>
<P>For patients using intermittent catheterisation, the limited evidence available suggested that antibiotic prophylaxis reduces the number of episodes of bacteriuria (asymptomatic and symptomatic). For patients using urethral catheterisation, limited data were available.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Is giving antibiotics, if microbiologically indicated, better than giving antibiotics if clinically indicated?</HEADING>
<P>None of the trials included in the review address this question.</P>
</SUBSECTION>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-07-09 15:28:47 +0100" MODIFIED_BY="[Empty name]">
<P>There is a need for large randomised trials to determine the optimal catheter policies for the long-term bladder drainage in adults and children. The most important patient groups are the frail, elderly and younger people with neurogenic bladder problems. Although there was some evidence in favour of antibiotic prophylaxis, the implications of general adoption of this policy are unclear and should be evaluated especially in terms of adverse effects, development of antibiotic resistance and economic implications. Trials comparing intermittent, indwelling urethral and suprapubic policies are also needed. Cross-over trials should report their data correctly, i.e. the difference between the treatments and its standard error.</P>
<P>Primary outcomes should include symptomatic urinary tract infection, measured both by the rate of infection and the number of patients having at least one episode of infection, and the development of resistant strains, preferably investigated over a longer period than the trials to date. With respect to patients receiving intermittent catheterisation, the outcome infection should be reported separately for patients learning the technique as opposed to those who have mastered the technique. <I>
<BR/>
</I>
</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-06-04 12:35:52 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to thank Sheila Wallace from the Cochrane Incontinence Group for her collaboration.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-07-09 15:29:32 +0100" MODIFIED_BY="Charlotte Archibald">
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-07-09 15:29:22 +0100" MODIFIED_BY="[Empty name]">
<P>All reviewers contributed to writing the review.</P>
<P>LAS and EMKS updated the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-07-09 15:34:05 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-07-09 15:33:17 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-07-09 15:32:39 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1980" NAME="Anderson 1980" YEAR="1980">
<REFERENCE NOTES="&lt;p&gt;{1060}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson RU</AU>
<TI>Prophylaxis of bacteriuria during intermittent catheterization of the acute neurogenic bladder</TI>
<SO>Journal of Urology</SO>
<YR>1980</YR>
<VL>123</VL>
<NO>3</NO>
<PG>364-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duffy-1982" NAME="Duffy 1982" YEAR="1982">
<REFERENCE NOTES="&lt;p&gt;{1058}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Duffy L, Smith AD</AU>
<TI>Nitrofurantoin macrocrystals prevent bacteriuria in intermittent self-catheterization</TI>
<SO>Urology</SO>
<YR>1982</YR>
<VL>20</VL>
<NO>1</NO>
<PG>47-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gribble-1993" NAME="Gribble 1993" YEAR="1993">
<REFERENCE NOTES="&lt;p&gt;{1241}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gribble MJ, Puterman ML</AU>
<TI>Prophylaxis of urinary tract infection in persons with recent spinal cord injury: a prospective, randomized, double-blind, placebo-controlled study of trimethoprim-sulfamethoxazole</TI>
<SO>American Journal of Medicine</SO>
<YR>1993</YR>
<VL>95</VL>
<NO>2</NO>
<PG>141-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1994" NAME="Johnson 1994" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;{1343}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson HW, Anderson JD, Chambers GK, Arnold WJ, Irwin BJ, Brinton JR</AU>
<TI>A short-term study of nitrofurantoin prophylaxis in children managed with clean intermittent catheterization</TI>
<SO>Pediatrics</SO>
<YR>1994</YR>
<VL>93</VL>
<NO>5</NO>
<PG>752-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohler-1987a" NAME="Mohler 1987a" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;{1188}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohler JL, Cowen DL, Flanigan RC</AU>
<TI>Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder</TI>
<SO>Journal of Urology</SO>
<YR>1987</YR>
<VL>138</VL>
<NO>2</NO>
<PG>336-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rutschmann-1995" NAME="Rutschmann 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;{6983}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rutschmann OT, Zwahlen A</AU>
<TI>Use of norfloxacin for prevention of symptomatic urinary tract infection in chronically catheterized patients</TI>
<SO>Journal of Clinical Microbiology and Infectious Diseases</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>441-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schlager-1998" NAME="Schlager 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;{6706}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schlager TA, Anderson S, Trudell J, Hendley JO</AU>
<TI>Nitrofurantoin prophylaxis for bacteriuria and urinary tract infection in children with neurogenic bladder on intermittent catheterization</TI>
<SO>Journal of Pediatrics</SO>
<YR>1998</YR>
<VL>132</VL>
<PG>704-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zegers-2011" MODIFIED="2012-07-09 15:32:39 +0100" MODIFIED_BY="[Empty name]" NAME="Zegers 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-07-09 15:32:39 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Zegers B, Uiterwaal C, Kimpen J, van Gool J, de Jong T, Winkler-Seinstra P, et al</AU>
<TI>Antibiotic prophylaxis for urinary tract infections in children with spina bifida on intermittent catheterization</TI>
<SO>Journal of Urology</SO>
<YR>2011</YR>
<VL>186</VL>
<NO>6</NO>
<PG>2365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-07-09 15:33:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2005" MODIFIED="2009-08-05 08:54:06 +0100" MODIFIED_BY="[Empty name]" NAME="Chen 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-05 08:53:38 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen TY, Ponsot Y, Carmel M, Bouffard N, Kennelly MJ, Tu LM</AU>
<TI>Multi-centre study of intraurethral valve-pump catheter in women with a hypocontractile or acontractile bladder</TI>
<SO>European Urology</SO>
<YR>2005</YR>
<VL>48</VL>
<NO>4</NO>
<PG>628-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-05 08:54:06 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Clarke-2005" MODIFIED="2012-07-09 15:32:51 +0100" MODIFIED_BY="[Empty name]" NAME="Clarke 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-09 15:32:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Clarke SA, Samuel M, Boddy SA</AU>
<TI>Are prophylactic antibiotics necessary with clean intermittent catheterization? A randomized controlled trial</TI>
<SO>Journal of Pediatric Surgery</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>3</NO>
<PG>568-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Day-2003" MODIFIED="2009-08-05 08:56:17 +0100" MODIFIED_BY="[Empty name]" NAME="Day 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-05 08:56:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Day RA, Moore KN, Albers MK</AU>
<TI>A pilot study comparing two methods of intermittent catheterization: limitations and challenges</TI>
<SO>Urologic Nursing</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>2</NO>
<PG>143-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jannelli-2007" MODIFIED="2009-08-05 08:59:40 +0100" MODIFIED_BY="[Empty name]" NAME="Jannelli 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-05 08:59:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jannelli ML, Wu JM, Plunkett LW, Williams KS, Visco AG</AU>
<TI>A randomized controlled trial of clean intermittent self-catheterization versus suprapubic catheterization after urogynecologic surgery</TI>
<SO>American Journal of Obstetrics &amp; Gynecology</SO>
<YR>2007</YR>
<VL>197</VL>
<NO>1</NO>
<PG>72-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kuhlemeier-1985" NAME="Kuhlemeier 1985" YEAR="1985">
<REFERENCE NOTES="&lt;p&gt;{1198}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kuhlemeier KV, Stover SL, Lloyd LK</AU>
<TI>Prophylactic antibacterial therapy for preventing urinary tract infections in spinal cord injury patients</TI>
<SO>Journal of Urology</SO>
<YR>1985</YR>
<VL>134</VL>
<NO>3</NO>
<PG>514-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maynard-1984" NAME="Maynard 1984" YEAR="1984">
<REFERENCE NOTES="&lt;p&gt;{984}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Maynard FM, Diokno AC</AU>
<TI>Urinary infection and complications during clean intermittent catheterization following spinal cord injury</TI>
<SO>Journal of Urology</SO>
<YR>1984</YR>
<VL>132</VL>
<NO>5</NO>
<PG>943-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mohler-1987b" NAME="Mohler 1987b" YEAR="1987">
<REFERENCE NOTES="&lt;p&gt;{1188}&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mohler JL, Cowen DL, Flanigan RC</AU>
<TI>Suppression and treatment of urinary tract infection in patients with an intermittently catheterized neurogenic bladder</TI>
<SO>Journal of Urology</SO>
<YR>1987</YR>
<VL>138</VL>
<NO>2</NO>
<PG>336-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naik-2005" MODIFIED="2012-07-05 20:51:15 +0100" MODIFIED_BY="[Empty name]" NAME="Naik 2005" YEAR="2005">
<REFERENCE MODIFIED="2012-07-05 20:51:15 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Naik R, Maughan K, Nordin A, Lopes A, Godfrey KA, Hatem MH</AU>
<TI>A prospective randomised controlled trial of intermittent self-catheterisation vs. supra-pubic catheterisation for post-operative bladder care following radical hysterectomy</TI>
<SO>Gynecologic Oncology</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>2</NO>
<PG>437-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ratahi-2005" MODIFIED="2009-08-05 09:40:44 +0100" MODIFIED_BY="[Empty name]" NAME="Ratahi 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-05 09:40:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Ratahi E, Lynskey T</AU>
<TI>Preoperative urethral catheterisation in patients undergoing total hip and knee arthroplasty</TI>
<SO>Journal of Bone &amp; Joint Surgery - British Volume</SO>
<YR>2005</YR>
<VL>87-B, Suppl 1</VL>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saint-2006" MODIFIED="2009-08-05 09:24:11 +0100" MODIFIED_BY="[Empty name]" NAME="Saint 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-05 09:24:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saint S, Kaufman SR, Rogers MA, Baker PD, Ossenkop K, Lipsky BA</AU>
<TI>Condom versus indwelling urinary catheters: a randomized trial</TI>
<SO>Journal of the American Geriatrics Society</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>7</NO>
<PG>1055-61</PG>
<IDENTIFIERS MODIFIED="2009-08-05 09:24:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-05 09:24:11 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="22370"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schumm-2008a" MODIFIED="2012-07-09 15:33:03 +0100" MODIFIED_BY="[Empty name]" NAME="Schumm 2008a" YEAR="2008">
<REFERENCE MODIFIED="2012-07-09 15:33:03 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Schumm K, N'Dow J, Norrie J and the CATHETER Study Group 2008</AU>
<TI>Recruitment challenges in a large randomised controlled trial with complex processes (Abstract number P06)</TI>
<SO>Proceedings of the 29th Society for Clinical Trials Annual Meeting, 18-21 May 2008, St Louis (MO)</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souto-2000" MODIFIED="2012-07-09 15:33:17 +0100" MODIFIED_BY="[Empty name]" NAME="Souto 2000" YEAR="2000">
<REFERENCE MODIFIED="2012-07-09 15:33:17 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souto CA, Teloken C, Souto JC, Rhoden EL, Ting HY</AU>
<TI>Experience with early catheter removal after radical retropubic prostatectomy</TI>
<SO>Journal of Urology</SO>
<YR>2000</YR>
<VL>163</VL>
<NO>3</NO>
<PG>865-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Souto-2004" MODIFIED="2009-08-05 09:30:52 +0100" MODIFIED_BY="[Empty name]" NAME="Souto 2004" YEAR="2004">
<REFERENCE MODIFIED="2009-08-05 09:30:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Souto CA, Rhoden EL, De Conti R, Chammas M Jr, Laste SE, Fornari A, et al</AU>
<TI>Urethral catheter removal 7 or 14 days after radical retropubic prostatectomy: clinical implications and complications in a randomized study</TI>
<SO>Revista do Hospital das Clinicas; Faculdade de Medicina Da Universidade de Sao Paulo</SO>
<YR>2004</YR>
<VL>59</VL>
<NO>5</NO>
<PG>262-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sublett-2007" MODIFIED="2009-08-05 09:15:27 +0100" MODIFIED_BY="[Empty name]" NAME="Sublett 2007" YEAR="2007">
<REFERENCE MODIFIED="2009-08-05 09:15:27 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sublett CM</AU>
<TI>Critique of 'Effect of time of day for urinary catheter removal on voiding behaviours in stroke patients'--the meaning of significance to the evidence base</TI>
<SO>Urologic Nursing</SO>
<YR>2007</YR>
<VL>27</VL>
<NO>3</NO>
<PG>236-8</PG>
<IDENTIFIERS MODIFIED="2009-08-05 09:15:12 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-08-05 09:15:12 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="23784"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2006" MODIFIED="2009-08-05 09:17:00 +0100" MODIFIED_BY="[Empty name]" NAME="Tang 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-05 09:17:00 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang MW, Kwok TC, Hui E, Woo J</AU>
<TI>Intermittent versus indwelling urinary catheterization in older female patients</TI>
<SO>Maturitas</SO>
<YR>2006</YR>
<VL>53</VL>
<NO>3</NO>
<PG>274-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turi-2006" MODIFIED="2009-08-05 09:19:11 +0100" MODIFIED_BY="[Empty name]" NAME="Turi 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-05 09:19:11 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turi MH, Hanif S, Fasih Q, Shaikh MA</AU>
<TI>Proportion of complications in patients practicing clean intermittent self-catheterization (CISC) vs indwelling catheter</TI>
<SO>Journal of the Pakistan Medical Association</SO>
<YR>2006</YR>
<VL>56</VL>
<NO>9</NO>
<PG>401-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waites-2006" MODIFIED="2009-08-05 09:20:40 +0100" MODIFIED_BY="[Empty name]" NAME="Waites 2006" YEAR="2006">
<REFERENCE MODIFIED="2009-08-05 09:20:40 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Waites KB, Canupp KC, Roper JF, Camp SM, Chen Y</AU>
<TI>Evaluation of 3 methods of bladder irrigation to treat bacteriuria in persons with neurogenic bladder</TI>
<SO>Journal of Spinal Cord Medicine</SO>
<YR>2006</YR>
<VL>29</VL>
<NO>3</NO>
<PG>217-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warren-1982b" MODIFIED="2009-08-05 09:30:06 +0100" MODIFIED_BY="[Empty name]" NAME="Warren 1982b" YEAR="1982">
<REFERENCE MODIFIED="2009-08-05 09:30:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;{729}&lt;/p&gt;" NOTES_MODIFIED="2009-08-05 09:30:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW, Anthony WC, Hoopes JM, Muncie HL Jr</AU>
<TI>Cephalexin for susceptible bacteriuria in afebrile, long-term catheterized patients</TI>
<SO>JAMA</SO>
<YR>1982</YR>
<VL>248</VL>
<NO>4</NO>
<PG>454-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-07-09 15:34:05 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-07-09 15:34:05 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Bouter-1995" MODIFIED="2008-10-30 16:26:42 +0000" MODIFIED_BY="[Empty name]" NAME="Bouter 1995" TYPE="BOOK">
<AU>Bouter LM, van Dongen MCJM</AU>
<SO>Epidemiologisch onderzoek. Opzet en interpretatie</SO>
<YR>1995</YR>
<PB>Bohn Stafleu Van Loghum</PB>
<CY>Houten, The Netherlands</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hagen-2010" MODIFIED="2012-07-09 15:33:33 +0100" MODIFIED_BY="[Empty name]" NAME="Hagen 2010" TYPE="COCHRANE_REVIEW">
<AU>Hagen S, Sinclair L, Cross S</AU>
<TI>Washout policies in long-term indwelling urinary catheterisation in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2010</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-07-05 21:18:00 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 21:18:00 +0100" MODIFIED_BY="Charlotte Archibald" TYPE="DOI" VALUE="10.1002/14651858.CD004012.pub4"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" MODIFIED="2012-07-05 20:58:16 +0100" MODIFIED_BY="Charlotte Archibald" NAME="Higgins 2005" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]</TI>
<SO>www.cochrane.org/resources/handbook/hbook.htm (accessed 31 May 2005)</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Huth-1992" NAME="Huth 1992" NOTES="&lt;p&gt;15405&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Huth TS, Burke JP, Larsen RA, Classen DC, Stevens LE</AU>
<TI>Randomized trial of meatal care with silver sulfadiazine cream for the prevention of catheter-associated bacteriuria</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1992</YR>
<VL>165</VL>
<PG>14-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92091861"/>
<IDENTIFIER TYPE="OTHER" VALUE="15405"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jahn-2007" MODIFIED="2012-07-09 15:33:42 +0100" MODIFIED_BY="[Empty name]" NAME="Jahn 2007" TYPE="COCHRANE_REVIEW">
<AU>Jahn P, Preuss M, Kernig A, Langer G, Seifert-Huehmer A</AU>
<TI>Types of indwelling urinary catheters for long-term bladder drainage in adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2012-07-05 21:18:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 21:18:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004997.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Jamison-2011" MODIFIED="2012-07-09 15:33:49 +0100" MODIFIED_BY="[Empty name]" NAME="Jamison 2011" TYPE="COCHRANE_REVIEW">
<AU>Jamison J, Maguire S, McCann J</AU>
<TI>Catheter policies for management of long term voiding problems in adults with neurogenic bladder disorders</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>12</NO>
<IDENTIFIERS MODIFIED="2012-06-07 15:34:39 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-07 15:34:39 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004375.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Liedl-2001" NAME="Liedl 2001" NOTES="&lt;p&gt;15406&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Liedl B</AU>
<TI>Catheter-associated urinary tract infections</TI>
<SO>Current Opinion in Urology</SO>
<YR>2001</YR>
<VL>11</VL>
<PG>75-9</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21067222"/>
<IDENTIFIER TYPE="OTHER" VALUE="15406"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Moore-2007" MODIFIED="2012-07-09 15:33:56 +0100" MODIFIED_BY="[Empty name]" NAME="Moore 2007" TYPE="COCHRANE_REVIEW">
<AU>Moore KN, Fader M, Getliffe K</AU>
<TI>Long-term bladder management by intermittent catheterisation in adults and children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2012-07-05 21:24:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 21:24:35 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD006008.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Nicolle-2001" NAME="Nicolle 2001" NOTES="&lt;p&gt;15407&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Nicolle LE</AU>
<TI>The chronic indwelling catheter and urinary infection in long term-care facility residents</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>2001</YR>
<VL>55</VL>
<NO>5</NO>
<PG>316-21</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21321241"/>
<IDENTIFIER TYPE="OTHER" VALUE="15407"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Platt-1986" NAME="Platt 1986" NOTES="&lt;p&gt;15408&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Platt R, Polk BF, Murdock B, Rosner B</AU>
<TI>Risk factors for nosocomial urinary tract infection</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1986</YR>
<VL>124</VL>
<NO>6</NO>
<PG>977-85</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="87046031"/>
<IDENTIFIER TYPE="OTHER" VALUE="15408"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Schumm-2008b" MODIFIED="2012-07-09 15:34:05 +0100" MODIFIED_BY="[Empty name]" NAME="Schumm 2008b" TYPE="COCHRANE_REVIEW">
<AU>Schumm K, Lam TBL</AU>
<TI>Types of urethral catheters for management of short-term voiding problems in hospitalised adults</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2012-07-05 21:28:10 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-07-05 21:28:10 +0100" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD004013.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shapiro-1984" NAME="Shapiro 1984" NOTES="&lt;p&gt;15409&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Shapiro M, Simchen E, Izraeli S, Sacks TG</AU>
<TI>A multivariate analysis of risk factors for acquiring bacteriuria in patients with indwelling urinary catheters for longer than 24 hours</TI>
<SO>Infection Control</SO>
<YR>1984</YR>
<VL>5</VL>
<NO>11</NO>
<PG>525-32</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="85053814"/>
<IDENTIFIER TYPE="OTHER" VALUE="15409"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Tambyah-1999" NAME="Tambyah 1999" NOTES="&lt;p&gt;15410&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Tambyah PA, Halvorson KT, Maki DG</AU>
<TI>A prospective study of pathogenesis of catheter-associated urinary tract infections</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1999</YR>
<VL>74</VL>
<PG>131-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="99166879"/>
<IDENTIFIER TYPE="OTHER" VALUE="15410"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Ware-1992" NAME="Ware 1992" NOTES="&lt;p&gt;4&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ware JE, Sherbourne CD</AU>
<TI>The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection</TI>
<SO>Medical Care</SO>
<YR>1992</YR>
<VL>30</VL>
<NO>6</NO>
<PG>473-83</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="92278120"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warren-1982a" MODIFIED="2008-10-30 16:30:48 +0000" MODIFIED_BY="[Empty name]" NAME="Warren 1982a" NOTES="&lt;p&gt;15411&lt;/p&gt;" NOTES_MODIFIED="2008-10-30 16:30:48 +0000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW, Tenney JH, Hoopes JM, Muncie HL, Anthony WC</AU>
<TI>A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>1982</YR>
<VL>146</VL>
<PG>719-23</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83058248"/>
<IDENTIFIER TYPE="OTHER" VALUE="15411"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warren-1994" NAME="Warren 1994" NOTES="&lt;p&gt;15412&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW</AU>
<TI>Catheter-associated bacteriuria in long-term care facilities</TI>
<SO>Infection Control &amp; Hospital Epidemiology</SO>
<YR>1994</YR>
<VL>15</VL>
<PG>557-62</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="95074474"/>
<IDENTIFIER TYPE="OTHER" VALUE="15412"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warren-1997" NAME="Warren 1997" NOTES="&lt;p&gt;15413&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW</AU>
<TI>Catheter-associated urinary tract infections</TI>
<SO>Infectious Diseases Clinics of North America</SO>
<YR>1997</YR>
<VL>11</VL>
<NO>3</NO>
<PG>609-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="98017686"/>
<IDENTIFIER TYPE="OTHER" VALUE="15413"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Warren-2001" NAME="Warren 2001" NOTES="&lt;p&gt;15414&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Warren JW</AU>
<TI>Catheter-associated urinary tract infections</TI>
<SO>International Journal of Antimicrobial Agents</SO>
<YR>2001</YR>
<VL>17</VL>
<PG>299-303</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="21193053"/>
<IDENTIFIER TYPE="OTHER" VALUE="15414"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Zigmond-1983" NAME="Zigmond 1983" NOTES="&lt;p&gt;1233&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Zigmond AS, Snaith RP</AU>
<TI>The hospital anxiety and depression scale</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1983</YR>
<VL>67</VL>
<NO>6</NO>
<PG>361-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="83279108"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-07-09 15:32:20 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-07-09 15:31:48 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2011-12-03 20:49:22 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1980">
<CHAR_METHODS MODIFIED="2011-12-03 20:41:48 +0000" MODIFIED_BY="[Empty name]">
<P>RCT </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 20:49:22 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 31 hospitalised male patients with spinal cord injury and acute neurogenic bladder (within 30 days of injury) starting with sterile intermittent catheterisation every 4 or 8 hours to keep the bladder volume &lt; 500 ml</P>
<P>Exclusion criteria: No antibiotic prophylaxis</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prophylaxis (15):<BR/>100 mg nitrofurantoin macrocrystals prophylaxis once a day (oral)</P>
<P>Control (16):<BR/>No antibiotics</P>
<P>Duration of intervention:<BR/>1) Until a balanced bladder status was achieved (defined as post-void residual volume &lt; 100 ml);<BR/>2) Hospital discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of bacteriuria per catheterisation day (symptomatic and asymptomatic)<BR/>Overall:<BR/>P:18/955; C: 36/686<BR/>In subgroups:<BR/>a) Catheterisation frequency every 4 hours: P: 4/577; C: 27/568<BR/>b) Catheterisation frequency every 8 hours: P: 14/378; C: 9/118</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Significant bacteriuria defined as 10,000 cfu/ml in fresh catheterised specimen<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:29:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Duffy-1982">
<CHAR_METHODS MODIFIED="2012-07-09 15:29:44 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 20:57:35 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 31 volunteers with neurogenic bladder using intermittent self-<BR/>catheterisation every 4 hours</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prophylaxis (31):<BR/>100 mg nitrofurantoin macrocrystals prophylaxis twice daily for three months (oral)</P>
<P>Control (31):<BR/>Matching placebo (oral) twice daily for three months</P>
<P>Duration of intervention:<BR/>six months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-09 15:29:44 +0100" MODIFIED_BY="[Empty name]">
<P>Rate of bacteriuria per catheterisation week<BR/>(symptomatic + asymptomatic)<BR/>P: 9/90; C: 25/85</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:29:44 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Significant bacteriuria defined as &gt; 100,000 cfu/ml of at least one organism &gt; 100,000 cfu/ml</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:30:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gribble-1993">
<CHAR_METHODS MODIFIED="2011-12-03 21:10:39 +0000" MODIFIED_BY="[Empty name]">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-09 15:29:52 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 131 hospitalised patients with<BR/>1) Acute spinal cord injury 30 days or less prior to enrolment<BR/>2) Neurogenic bladder dysfunction<BR/>3) Commencement of clean intermittent catheterisation 72 hours or less prior to enrolment<BR/>4) Age 18 years or older</P>
<P>Exclusion criteria:<BR/>1) Known hypersensitivity to TMP or sulfenamide<BR/>2) Serum creatinine greater than 176 µmol/L<BR/>3) Serum transaminase levels greater than 3 times normal<BR/>4) Pregnancy</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-09 15:29:57 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Prophylaxis (66):<BR/>Low-dose TMP-SMX once daily (TMP 40 mg, SMX 200 mg) (oral)</P>
<P>Control (60):<BR/>Matching placebo</P>
<P>Duration of intervention<BR/>1) Until intermittent catheterisation was discontinued<BR/>2) Until discharge<BR/>3) For a maximum of 16 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>At least one episode of bacteriuria (symptomatic + asymptomatic):<BR/>Overall:<BR/>P: 49/66; C: 52/60<BR/>In subgroups:<BR/>a) In males: P: 42/57; C: 45/52<BR/>b) In females: P: 7/9; C: 7/8</P>
<P>At least 1 episode of definite symptomatic bacteriuria:<BR/>Overall:<BR/>P: 4/66; C: 19/60<BR/>In subgroups:<BR/>a) In males: P: 4/57; C: 18/52<BR/>b) In females: P: 0/9; C; 1/8</P>
<P>At least 1 adverse event:<BR/>P: 37/67; C: 40/62</P>
<P>At least 1 episode of need of antibiotics for UTI:<BR/>P: 41/66; C: 48/60</P>
<P>At least 1 episode of bacteriuria due to TMX-SMX resistant organisms:<BR/>P: 47/66; C: 45/60</P>
<P>At least 1 time recovery of TMX-SMX resistant gram-negative bacilli from weekly surveillance cultures:<BR/>P: 33/67; C: 26/62</P>
<P>Rate of adverse events per catheterisation week:<BR/>P: 66/613; C: 85/582</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:30:15 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Significant bacteriuria defined as &#8805; 100 cfu/ml of an organism in 2 consecutive urine specimens or &#8805;<BR/>100,000 from a single specimen</P>
<P>Symptomatic urinary tract infection defined as having bacteriuria and fever &gt; 38 °C and at least one classical manifestation of UTI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:30:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-1994">
<CHAR_METHODS MODIFIED="2012-07-09 15:30:36 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Cross-over study (method of allocation not stated, double-blind)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 21:17:40 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 66 children with neurogenic bladder due to meningomyelocele and clean intermittent catheterisation at home</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-07-09 15:30:36 +0100" MODIFIED_BY="[Empty name]">
<P>Prophylaxis (56):<BR/>Nitrofurantoin once daily (oral): 25 mg nitrofurantoin for children weighing between 12.5 and 25 kg; 50 mg nitrofurantoin for children &gt; 25 kg</P>
<P>Control (56):<BR/>Matching placebo</P>
<P>Duration of intervention:<BR/>24 weeks (2 times 12 weeks)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of clinical urinary tract infection per catheterisation week:<BR/>P: 4/430; C: 2/389</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Clinical infection defined as one or more of the following: flank or abdominal pain, pyrexia, incontinence ascribed by a physician to a urinary tract infection</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:30:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mohler-1987a">
<CHAR_METHODS>
<P>RCT (randomisation table, double-blind)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 21:20:00 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 47 adult patients admitted to a rehabilitation facility with sterile intermittently catheterised neurogenic bladder<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prophylaxis (21):<BR/>160 mg trimethoprim and 800 mg sulfamethoxazole once a day (oral)</P>
<P>Control (25):<BR/>Matching placebo</P>
<P>Duration of intervention:<BR/>until hospital discharge</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of bacteriuria per catheterisation day (symptomatic + asymptomatic):<BR/>P: 36/914; C: 48/1022</P>
<P>Rate of asymptomatic bacteriuria: <BR/>P: 25/914; C: 26/1022</P>
<P>Rate of symptomatic bacteriuria:<BR/>P: 11/914; C: 22/1022</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:30:45 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Asymptomatic urinary tract infection defined as<BR/>a) &#8805; 10,000 cfu/ml of a single or predominant species in a (sterile) catheterised specimen<BR/>b) &#8805; 10,000 cfu/ml of a single or predominant species in a clean-catch specimen in male patients with suspected symptomatic UTI<BR/>c) &#8805; 100,000 cfu/ml of a single or predominant species in a clean-catch specimen in asymptomatic male patients</P>
<P>Symptomatic urinary tract infection defined as asymptomatic UTI plus T &gt; 38 °C , white blood cell count &gt; 104, clinical symptoms of UTI and no other apparent source of infection</P>
<P>Total UTI defined as symptomatic and asymptomatic UTI</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:30:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rutschmann-1995">
<CHAR_METHODS MODIFIED="2012-07-04 21:27:30 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 21:22:09 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 34 elderly inpatients (nursing home) with long-term urethral catheters</P>
<P>The results of 23 patients were analysed</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prophylaxis (34):<BR/>200 mg norfloxacin daily for 3 months (oral)</P>
<P>Control (34):<BR/>Matching placebo</P>
<P>Duration of intervention:<BR/>6 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-07-04 21:27:58 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Rate of symptomatic UTI per catheterisation week:<BR/>P: 1/276; C: 12/259</P>
<P>Rate of visual encrustation per catheterisation week:<BR/>P: 4/276; C: 19/259</P>
<P>Rate of catheter
 obstruction per catheterisation week:<BR/>P: 2/276; C: 8/259</P>
<P>Rate of adverse events per catheterisation week:<BR/>P: 596/276; C: 744/259</P>
<P>Patients' general condition (number of patients not improved/ number of study participants):<BR/>P: 12/23; C: 1/23</P>
<P>Microbial resistance pattern (resistant strains/total no. of strains)<BR/>P: 20/22; C: 8/41</P>
<P>Spectrum of microbial isolates (no. of gram-negative strains/total no. of strains)<BR/>P: 5/22; C: 31/41</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:30:59 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Symptomatic urinary tract infection defined as bacteriuria &#8805; 100,000 cfu/ml and</P>
<P>a) T &#8805; 38.5 °C for two consecutive days in the absence of other clinical sources of infection or<BR/>b) Flank pain or unexplained mental disturbance or abdominal discomfort</P>
<P>Adverse events defined as obstruction, encrustation, leakage, suprapubic pain, inflammation of meatus, haematuria and side effects of treatment.</P>
<P>Patients' general condition defined as unchanged during the entire study period or improved during one or the other period. Criteria included well-being of the patient, appreciation of his or her social involvement, awareness, need for nursing care and functional status<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:31:13 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schlager-1998">
<CHAR_METHODS MODIFIED="2012-07-04 21:30:06 +0100" MODIFIED_BY="[Empty name]">
<P>Cross-over study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-12-03 21:23:42 +0000" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 16 children with chronic neurogenic bladder using clean intermittent catheterisation 4 times a day and living at home (14 meningomyelocele, 1 spinal cord injury)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Prophylaxis (16):<BR/>Nitrofurantoin once daily (25 mg nitrofurantoin for children &lt; 25 kg, 50 mg nitrofurantoin for children &gt; 25 kg) (oral)</P>
<P>Control (16):<BR/>Matching placebo</P>
<P>Duration of intervention:<BR/>10 months</P>
<P>Washout period:<BR/>1 month</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of symptomatic UTI per catheterisation week (first period):<BR/>P:5/139; C:11/153</P>
<P>Rate of symptomatic UTI per catheterisation week (both periods):<BR/>P: 9/319; C: 19/309</P>
<P>At least 1 episode of definite symptomatic UTI (both periods):<BR/>P: 8/15; C: 11/15</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:31:13 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Symptomatic urinary tract infection defined as bacteriuria &#8805; 10,000 cfu/ml with fever, abdominal pain, change in continence pattern, or change in colour or odour of urine</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-07-09 15:31:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zegers-2011">
<CHAR_METHODS MODIFIED="2011-12-03 21:24:24 +0000" MODIFIED_BY="[Empty name]">
<P>RCT parallel group</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-07-09 15:31:25 +0100" MODIFIED_BY="[Empty name]">
<P>Inclusion criteria: 176 children with known spina bifida performing clean intermittent catheterisation and using low dose chemoprophylaxis during preceding 6 months. They were allocated to continue or discontinue prophylaxis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-12-03 21:32:54 +0000" MODIFIED_BY="[Empty name]">
<P>Prophylaxis (88):</P>
<P>Trimethoprim, nitrofurantoin, cefuroxime, co-trimoxazole or a combination of prophylactics</P>
<P>Control (88)</P>
<P>No medicaments (placebo not used) </P>
<P>Duration:</P>
<P>18 months</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-12-03 21:40:55 +0000" MODIFIED_BY="[Empty name]">
<P>At least one episode of febrile UTI</P>
<P>P:2/88; C: 4/88</P>
<P>Rate of asymptomatic significant bacteriuria per participants year</P>
<P>P: 3.64; C: 4.58</P>
<P>Rate of afebrile UTI per participants year</P>
<P>P: 1.07; C: 1.52</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-07-09 15:31:32 +0100" MODIFIED_BY="[Empty name]">
<P>Signifcant bacteriuria was defined as more than 10<SUP>3 </SUP>cfu/ml. UTI was defined as significant bacteriuria, positive leukocyturia and clinical symptoms such as increasing incontinence and foul smell or cloudiness of urine with or without fever greater than 38.5 °C.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>cfu/ml = colony-forming units per millilitre</P>
<P>C = control group</P>
<P>P = prophylaxis group</P>
<P>RCT = randomised controlled trial</P>
<P>SMX = sulfamethoxazole</P>
<P>T = temperature<BR/>TMP = trimethoprim<BR/>TMP-SMX = trimethoprim and sulfamethoxazole<BR/>UTI = urinary tract infection</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-07-09 15:32:20 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:35:02 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:35:02 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-04 12:35:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Clarke-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-04 12:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>The study had high risk of attrition bias.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:35:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Day-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:35:20 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:35:34 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jannelli-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:35:34 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review (short-term setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-09 15:32:06 +0100" MODIFIED_BY="Charlotte Archibald" STUDY_ID="STD-Kuhlemeier-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-09 15:32:06 +0100" MODIFIED_BY="Charlotte Archibald">
<P>The study methods were insufficiently described to judge eligibility.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-09 15:31:58 +0100" MODIFIED_BY="Charlotte Archibald" STUDY_ID="STD-Maynard-1984">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-09 15:31:58 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Authors did not present sufficient data to calculate incidence densities.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-09 15:32:02 +0100" MODIFIED_BY="Charlotte Archibald" STUDY_ID="STD-Mohler-1987b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-09 15:32:02 +0100" MODIFIED_BY="Charlotte Archibald">
<P>Trialists tried to answer three different questions. We did not include the following two comparisons because the study methods were too unclear: 'antibiotics if microbiologically indicated versus antibiotics when clinically indicated' and 'three days antibiotics versus 10 days antibiotics'.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:36:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Naik-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:36:28 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review (short-term setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:36:39 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ratahi-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:36:39 +0100" MODIFIED_BY="[Empty name]">
<P>Not published as an article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:37:12 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saint-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:37:12 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review (short-term setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:37:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schumm-2008a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:37:25 +0100" MODIFIED_BY="[Empty name]">
<P>Not published as an article.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:37:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Souto-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:37:54 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:38:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Souto-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-04 21:36:37 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sublett-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-04 21:36:37 +0100" MODIFIED_BY="[Empty name]">
<P>Not RCT.
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:39:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:39:11 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review (short-term setting).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-09 15:32:14 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turi-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-09 15:32:14 +0100" MODIFIED_BY="[Empty name]">
<P>Authors did not present sufficient data to calculate incidence densities.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-05 09:39:57 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Waites-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-05 09:39:57 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not answer any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-09 15:32:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warren-1982b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-09 15:32:20 +0100" MODIFIED_BY="[Empty name]">
<P>This study did not address any of the questions posed in the review.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 20:44:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>Randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 20:56:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-09 15:30:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>Block randomisation in groups of eight which was pre-stratified into two groups: presence or absence of prior bacteriuria and sex; the randomisation scheme was obtained from a separate computer-generated randomisation schedule</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:14:46 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-09 15:30:50 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>Randomisation table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:20:30 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:22:37 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>Computer-
based random concealed allocation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2011-12-03 22:14:47 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:09:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 20:56:20 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>Not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:08:57 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:15:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:18:42 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:20:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:22:54 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>Not stated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 22:14:47 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-12-03 20:39:07 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 20:44:50 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 20:56:32 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 21:09:31 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 21:15:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 21:18:58 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>Double-blind </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 21:21:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-12-03 21:23:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2011-12-03 22:15:13 +0000" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 20:46:47 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 20:57:19 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 21:09:50 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 21:15:37 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 21:19:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 21:21:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 21:23:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-12-03 22:15:13 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>Outcome assessor blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-03 20:47:25 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>No losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-03 20:57:52 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>No losses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-09 15:30:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>a) Excluded from study: Control: 2 did not receive study medication<BR/>b) 44 patients did not complete the study:<BR/>Prophylaxis: 12 second relapse; 7 suspected adverse effects; 3 withdrew consent; 3 others. Control: 10 second relapse; 5 suspected adverse effects; 2 withdrew consent; 2 others<BR/>c) 3 patients were excluded from efficacy analysis: prophylaxis: 1; control: 2</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-04 21:25:03 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>a) Excluded from study: 10 patients were not started on study medication<BR/>b) 4 patients dropped out but were included in the intention-
to-
treat analysis: 1 patient in group I during the first period (antibiotic prophylaxis) due to an increased number of UTIs; 3 patients in group II during the first period (placebo): 2 patients because of dissatisfaction with the number of UTIs and 1 family moved</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-01-31 11:29:07 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>1 patient was eliminated from the study because of protocol violation (extended antibiotic administration)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-12-03 21:22:00 +0000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>11 patients did not complete the study: In 4 patients the catheter was withdrawn (numbers not reported according to allocated group); Prophylaxis: 3 died of non-infectious causes; Control: 3 died of non-infectious causes, 1 died of septic shock</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-09 15:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>One child was discontinued from study because of a 4-week hospitalisation for torsion of an ovarian cyst</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-09 15:31:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>No losses post randomisation. 38 (43%) switched back to prophylaxis group, analyses by intention-
to-
treat principles.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2011-12-03 22:20:22 +0000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 20:48:49 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anderson-1980">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 20:58:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Duffy-1982">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:14:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gribble-1993">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:18:14 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-1994">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:20:12 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mohler-1987a">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:22:24 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rutschmann-1995">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 21:24:00 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schlager-1998">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-12-03 22:20:22 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zegers-2011">
<DESCRIPTION>
<P>All outcomes related</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2011-12-03 20:48:14 +0000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-07-09 15:40:02 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-07-09 15:34:41 +0100" MODIFIED_BY="Charlotte Archibald" NO="1">
<NAME>Indwelling catheter versus suprapubic catheter</NAME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-07-09 15:34:53 +0100" MODIFIED_BY="Charlotte Archibald" NO="2">
<NAME>Indwelling catheter versus intermittent catheterisation</NAME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2012-07-09 15:34:59 +0100" MODIFIED_BY="Charlotte Archibald" NO="3">
<NAME>Suprapubic catheter versus intermittent catheterisation</NAME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2012-07-09 15:40:02 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Prophylactic antibiotic versus antibiotic for symptomatic UTI</NAME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-06-08 13:04:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Rate of symptomatic UTI per catheterisation week - cross-over trial</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDR, 95% CI</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-06-08 13:03:44 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Intermittent catheterisation</NAME>
<IV_DATA CI_END="1.4400885046488197" CI_START="0.17382528850387574" EFFECT_SIZE="0.5003236950132345" ESTIMABLE="YES" ESTIMATE="-0.6925" LOG_CI_END="0.15838918369209137" LOG_CI_START="-0.7598870411280951" LOG_EFFECT_SIZE="-0.3007489287180019" MODIFIED="2012-06-08 13:03:44 +0100" MODIFIED_BY="[Empty name]" ORDER="7265" SE="0.5394" STUDY_ID="STD-Schlager-1998" TOTAL_1="7" TOTAL_2="8" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES">
<NAME>Rate of symptomatic UTI - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.02.01" NO="1" STUDIES="1">
<NAME>Intermittent catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="35" STUDY_ID="STD-Johnson-1994">
<TR>
<TD>
<P>4 UTIs in 430 catherisation weeks</P>
</TD>
<TD>
<P>2 UTIs in 389 catheterisation weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
<OTHER_SUBGROUP ID="CMP-004.02.02" NO="2" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="36" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>1 UTI in 276 catheterisation weeks</P>
</TD>
<TD>
<P>12 UTIs in 259 catheterisation weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.03" NO="3" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>At least one episode of symptomatic urinary tract infection - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.03.01" NO="1" STUDIES="1">
<NAME>Intermittent catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="37" STUDY_ID="STD-Schlager-1998">
<TR>
<TD>
<P>8/15 study participants</P>
</TD>
<TD>
<P>11/15 study participants</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.04" NO="4" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Rate of visual encrustation - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.04.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="38" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>4 events in 276 catheterisation weeks</P>
</TD>
<TD>
<P>19 events in 259 catheterisation weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.05" NO="5" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Rate of catheter obstruction - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.05.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="39" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>2 events in 276 catheterisation weeks</P>
</TD>
<TD>
<P>8 events in 259 catheterisation weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.06" NO="6" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Rate of adverse events - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.06.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="40" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>596 events in 276 catheterisation weeks</P>
</TD>
<TD>
<P>744 events in 259 catheterisation weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.07" NO="7" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Patients general condition - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.07.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="41" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>12 patients improved / 23 study participants</P>
</TD>
<TD>
<P>1 patient improved / 23 study participants</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.08" NO="8" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Microbial resistance pattern (resistant strains/total number of strains) - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.08.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="42" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>20 resistant strains/22 isolated strains</P>
</TD>
<TD>
<P>8 resistant strains/41 isolated strains</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-004.09" NO="9" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES">
<NAME>Spectrum of microbial isolates (number of gram-neg. strains/total number of strains - cross-over trial</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_SUBGROUP ID="CMP-004.09.01" NO="1" STUDIES="1">
<NAME>Urethral catheterisation (both periods)</NAME>
<OTHER_DATA ORDER="43" STUDY_ID="STD-Rutschmann-1995">
<TR>
<TD>
<P>5 gram-neg. strains/ 22 isolated strains</P>
</TD>
<TD>
<P>31 gram-neg. strains/ 41isolated strains</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_SUBGROUP>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-09 15:39:51 +0100" MODIFIED_BY="[Empty name]" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of febrile symptomatic UTI. Parallel group trial</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="2" EVENTS_2="4" I2="0.0" ID="CMP-004.10.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:37:33 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Intermittent catheterisation</NAME>
<DICH_DATA CI_END="2.6599723329172837" CI_START="0.09398593996871252" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.42487711944165235" LOG_CI_START="-1.0269371107696148" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2011-12-02 23:19:39 +0000" MODIFIED_BY="[Empty name]" ORDER="33" O_E="0.0" SE="0.8528028654224418" STUDY_ID="STD-Zegers-2011" TOTAL_1="88" TOTAL_2="88" VAR="0.7272727272727273" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-004.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:40:02 +0100" MODIFIED_BY="[Empty name]" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="2.27" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Rate of afebrile symptomatic UTI per person year. Parallel group trial</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDR, 95% CI</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" ID="CMP-004.11.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:40:01 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0" Z="0.0">
<NAME>Intermittent catheterisation</NAME>
<IV_DATA CI_END="-0.1348043218551935" CI_START="-0.6051956781448065" EFFECT_SIZE="-0.37" ESTIMABLE="YES" ESTIMATE="-0.37" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-07-09 15:40:01 +0100" MODIFIED_BY="[Empty name]" ORDER="63" SE="0.12" STUDY_ID="STD-Zegers-2011" TOTAL_1="88" TOTAL_2="88" WEIGHT="0.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2012-07-09 15:39:20 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Prophylactic antibiotic versus antibiotic for laboratory UTI</NAME>
<IV_OUTCOME CHI2="11.989800353619163" CI_END="0.7148623965557352" CI_START="0.389088363064052" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="0.5273941976282221" ESTIMABLE="YES" I2="74.97873266009438" I2_Q="69.42832993100869" ID="CMP-005.01" LOG_CI_END="-0.14577754724477932" LOG_CI_START="-0.4099517579720057" LOG_DATA="YES" LOG_EFFECT_SIZE="-0.2778646526083925" NO="1" P_CHI2="0.007418193932699824" P_Q="0.037968429286616256" P_Z="3.738519657266786E-5" Q="6.542004396510186" RANDOM="NO" SCALE="5.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="38" TOTAL_2="43" WEIGHT="300.0" Z="4.123072499696161">
<NAME>Rate of bacteriuria (asymptomatic and symptomatic) per catheterisation week</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDR, 95% CI</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="5.447795957108976" CI_END="0.8650804413433979" CI_START="0.43524689146561973" DF="1" EFFECT_SIZE="0.6136151668288687" ESTIMABLE="YES" I2="81.64395274945875" ID="CMP-005.01.01" LOG_CI_END="-0.06294350686207495" LOG_CI_START="-0.36126432193182373" LOG_EFFECT_SIZE="-0.2121039143969493" NO="1" P_CHI2="0.01959311453632684" P_Z="0.0053191900724729076" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="41" WEIGHT="100.0" Z="2.7870400736253753">
<NAME>Overall</NAME>
<IV_DATA CI_END="0.6325105379913984" CI_START="0.20397831244434672" EFFECT_SIZE="0.35919135866937457" ESTIMABLE="YES" ESTIMATE="-1.0239" LOG_CI_END="-0.19893223449461064" LOG_CI_START="-0.6904160055468684" LOG_EFFECT_SIZE="-0.4446741200207396" ORDER="7275" SE="0.2887" STUDY_ID="STD-Anderson-1980" TOTAL_1="15" TOTAL_2="16" WEIGHT="36.84247098196729"/>
<IV_DATA CI_END="1.2919750042158227" CI_START="0.544344990949112" EFFECT_SIZE="0.838617983337074" ESTIMABLE="YES" ESTIMATE="-0.176" LOG_CI_END="0.11125411146390342" LOG_CI_START="-0.26412576909384805" LOG_EFFECT_SIZE="-0.0764358288149723" ORDER="7276" SE="0.2205" STUDY_ID="STD-Mohler-1987a" TOTAL_1="21" TOTAL_2="25" WEIGHT="63.15752901803271"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="0.4167156029861832" CI_START="0.051014330123285864" DF="0" EFFECT_SIZE="0.14580283720923018" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.02" LOG_CI_END="-0.3801602380501915" LOG_CI_START="-1.2923078117592313" LOG_EFFECT_SIZE="-0.8362340249047113" NO="2" P_CHI2="1.0" P_Z="3.260256090824502E-4" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="3.5936916759985067">
<NAME>Sub-category: catheterisation every four hours</NAME>
<IV_DATA CI_END="0.4167156029861832" CI_START="0.051014330123285864" EFFECT_SIZE="0.14580283720923018" ESTIMABLE="YES" ESTIMATE="-1.9255" LOG_CI_END="-0.3801602380501915" LOG_CI_START="-1.2923078117592313" LOG_EFFECT_SIZE="-0.8362340249047113" ORDER="7277" SE="0.5358" STUDY_ID="STD-Anderson-1980" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
<IV_SUBGROUP CHI2="0.0" CI_END="1.121757457779496" CI_START="0.21019983317352767" DF="0" EFFECT_SIZE="0.4855854512713602" ESTIMABLE="YES" I2="0.0" ID="CMP-005.01.03" LOG_CI_END="0.04989896553447744" LOG_CI_START="-0.6773676329882957" LOG_EFFECT_SIZE="-0.3137343337269092" NO="3" P_CHI2="1.0" P_Z="0.09083465671030255" STUDIES="1" TAU2="0.0" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0" Z="1.691011235955056">
<NAME>Sub-category: catheterisation every eight hours</NAME>
<IV_DATA CI_END="1.1217574577794958" CI_START="0.2101998331735277" EFFECT_SIZE="0.4855854512713602" ESTIMABLE="YES" ESTIMATE="-0.7224" LOG_CI_END="0.049898965534477355" LOG_CI_START="-0.6773676329882956" LOG_EFFECT_SIZE="-0.3137343337269092" ORDER="7278" SE="0.4272" STUDY_ID="STD-Anderson-1980" TOTAL_1="1" TOTAL_2="1" WEIGHT="100.0"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<OTHER_OUTCOME COLS="2" ID="CMP-005.02" NO="2" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Rate of bacteriuria (asymptomatic and symptomatic) - cross-over trial (both periods)</NAME>
<TR>
<TH>
<P>Treatment</P>
</TH>
<TH>
<P>Control</P>
</TH>
</TR>
<OTHER_DATA ORDER="50" STUDY_ID="STD-Duffy-1982">
<TR>
<TD>
<P>9 events in 90 weeks</P>
</TD>
<TD>
<P>25 events in 85 weeks</P>
</TD>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<IV_OUTCOME CHI2="3.6097530876440245" CI_END="-0.04758901311389703" CI_START="-0.23415777638640545" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-0.14087339475015123" ESTIMABLE="YES" I2="72.29727419797929" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" NO="3" P_CHI2="0.05744182526649555" P_Q="1.0" P_Z="0.0030779953894184914" Q="0.0" RANDOM="NO" SCALE="0.5" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="SUB" TOTAL_1="36" TOTAL_2="41" WEIGHT="99.99999999999999" Z="2.9598393133677994">
<NAME>Rate difference of bacteriuria (asymptomatic and symptomatic) per catheterisation week</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDD</EFFECT_MEASURE>
<IV_SUBGROUP CHI2="3.6097530876440245" CI_END="-0.04758901311389703" CI_START="-0.23415777638640545" DF="1" EFFECT_SIZE="-0.14087339475015123" ESTIMABLE="YES" I2="72.29727419797929" ID="CMP-005.03.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="1" P_CHI2="0.05744182526649555" P_Z="0.0030779953894184914" STUDIES="2" TAU2="0.0" TOTAL_1="36" TOTAL_2="41" WEIGHT="99.99999999999999" Z="2.9598393133677994">
<NAME>Overall</NAME>
<IV_DATA CI_END="-0.10035047426209825" CI_START="-0.3696495257379017" EFFECT_SIZE="-0.235" ESTIMABLE="YES" ESTIMATE="-0.235" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7280" SE="0.0687" STUDY_ID="STD-Anderson-1980" TOTAL_1="15" TOTAL_2="16" WEIGHT="47.99635069069129"/>
<IV_DATA CI_END="0.0753576229796436" CI_START="-0.1833576229796436" EFFECT_SIZE="-0.054" ESTIMABLE="YES" ESTIMATE="-0.054" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7281" SE="0.066" STUDY_ID="STD-Mohler-1987a" TOTAL_1="21" TOTAL_2="25" WEIGHT="52.0036493093087"/>
</IV_SUBGROUP>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="NO" LOG_EFFECT_SIZE="-Infinity" NO="4" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="YES" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0" Z="0.0">
<NAME>Rate difference of bacteriuria per catheterisation week - cross-over trial</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDD</EFFECT_MEASURE>
<IV_DATA CI_END="-0.015376608661273085" CI_START="-0.08162339133872692" EFFECT_SIZE="-0.0485" ESTIMABLE="YES" ESTIMATE="-0.0485" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7282" SE="0.0169" STUDY_ID="STD-Duffy-1982" TOTAL_1="31" TOTAL_2="31" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" NO="5" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Rate of symptomatic bacteriuria per catheterisation week</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDR, 95% CI</EFFECT_MEASURE>
<IV_DATA CI_END="1.1530547206073498" CI_START="0.2711143206899693" EFFECT_SIZE="0.5591150572966391" ESTIMABLE="YES" ESTIMATE="-0.5814" LOG_CI_END="0.06184991813069568" LOG_CI_START="-0.5668475416877969" LOG_EFFECT_SIZE="-0.2524988117785506" ORDER="7283" SE="0.3693" STUDY_ID="STD-Mohler-1987a" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_DATA="YES" LOG_EFFECT_SIZE="-Infinity" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0" Z="0.0">
<NAME>Rate of adverse events per catheterisation week</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<EFFECT_MEASURE>IDR</EFFECT_MEASURE>
<IV_DATA CI_END="1.0168708215389053" CI_START="0.5344430566840332" EFFECT_SIZE="0.7371970904148066" ESTIMABLE="YES" ESTIMATE="-0.3049" LOG_CI_END="0.007265785709256402" LOG_CI_START="-0.27209856077385935" LOG_EFFECT_SIZE="-0.13241638753230148" ORDER="7284" SE="0.1641" STUDY_ID="STD-Gribble-1993" TOTAL_1="1" TOTAL_2="1" WEIGHT="0.0"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="98" EVENTS_2="104" I2="0.0" I2_Q="0.0" ID="CMP-005.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-09 15:39:20 +0100" MODIFIED_BY="Charlotte Archibald" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="5.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="132" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of bacteriuria (asymptomatic and symptomatic)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="49" EVENTS_2="52" I2="0.0" ID="CMP-005.07.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:39:20 +0100" MODIFIED_BY="Charlotte Archibald" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Overall</NAME>
<DICH_DATA CI_END="1.0187698100153753" CI_START="0.7203176156840789" EFFECT_SIZE="0.8566433566433567" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.008076066701865498" LOG_CI_START="-0.14247596423088654" LOG_EFFECT_SIZE="-0.06719994876451052" ORDER="7285" O_E="0.0" SE="0.08843500821447087" STUDY_ID="STD-Gribble-1993" TOTAL_1="66" TOTAL_2="60" VAR="0.00782075067789353" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="42" EVENTS_2="45" I2="0.0" ID="CMP-005.07.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-05 21:06:18 +0100" MODIFIED_BY="Charlotte Archibald" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>Sub-category: male</NAME>
<DICH_DATA CI_END="1.028164716792564" CI_START="0.7051277929361481" EFFECT_SIZE="0.8514619883040936" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="45" LOG_CI_END="0.012062696238647107" LOG_CI_START="-0.15173216706891796" LOG_EFFECT_SIZE="-0.06983473541513545" ORDER="7286" O_E="0.0" SE="0.09621391350451346" STUDY_ID="STD-Gribble-1993" TOTAL_1="57" TOTAL_2="52" VAR="0.009257117151853997" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="7" EVENTS_2="7" I2="0.0" ID="CMP-005.07.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-05 21:06:28 +0100" MODIFIED_BY="Charlotte Archibald" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Sub-category: female</NAME>
<DICH_DATA CI_END="1.3753876768606963" CI_START="0.574473270397165" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="7" LOG_CI_END="0.13842512885043082" LOG_CI_START="-0.24073017374519343" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="7287" O_E="0.0" SE="0.22271770159368698" STUDY_ID="STD-Gribble-1993" TOTAL_1="9" TOTAL_2="8" VAR="0.049603174603174593" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="8" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-005.08" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2012-07-09 15:36:56 +0100" MODIFIED_BY="Charlotte Archibald" NO="8" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="132" TOTAL_2="120" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of definite symptomatic bacteriuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="19" I2="0.0" ID="CMP-005.08.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:36:26 +0100" MODIFIED_BY="Charlotte Archibald" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>Overall</NAME>
<DICH_DATA CI_END="0.530733778000641" CI_START="0.06901614249517572" EFFECT_SIZE="0.19138755980861244" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="-0.2751232712693095" LOG_CI_START="-1.1610493182968737" LOG_EFFECT_SIZE="-0.7180862947830916" ORDER="7288" O_E="0.0" SE="0.5203973454286509" STUDY_ID="STD-Gribble-1993" TOTAL_1="66" TOTAL_2="60" VAR="0.2708133971291866" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="18" I2="0.0" ID="CMP-005.08.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:36:40 +0100" MODIFIED_BY="Charlotte Archibald" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="57" TOTAL_2="52" WEIGHT="0.0" Z="0.0">
<NAME>Sub-category: male</NAME>
<DICH_DATA CI_END="0.560033021656197" CI_START="0.0733868611852347" EFFECT_SIZE="0.20272904483430798" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="18" LOG_CI_END="-0.2517863646004817" LOG_CI_START="-1.13438168702559" LOG_EFFECT_SIZE="-0.693084025813036" ORDER="7289" O_E="0.0" SE="0.5184408613098157" STUDY_ID="STD-Gribble-1993" TOTAL_1="57" TOTAL_2="52" VAR="0.26878092667566356" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-005.08.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" MODIFIED="2012-07-09 15:36:56 +0100" MODIFIED_BY="Charlotte Archibald" NO="3" P_CHI2="0.0" P_Z="0.0" STUDIES="1" TAU2="0.0" TOTAL_1="9" TOTAL_2="8" WEIGHT="0.0" Z="0.0">
<NAME>Sub-category: female</NAME>
<DICH_DATA CI_END="6.4710111695658785" CI_START="0.013908181834592291" EFFECT_SIZE="0.3" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.8109721494554388" LOG_CI_START="-1.856729640016114" LOG_EFFECT_SIZE="-0.5228787452803376" ORDER="7290" O_E="0.0" SE="1.567021236472421" STUDY_ID="STD-Gribble-1993" TOTAL_1="9" TOTAL_2="8" VAR="2.4555555555555553" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="4" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-005.09" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="9" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="0.5" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of definite symptomatic bacteriuria</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.12503437973402576" CI_START="-0.38708683238718633" EFFECT_SIZE="-0.25606060606060604" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="7291" O_E="0.0" SE="0.06685134388187662" STUDY_ID="STD-Gribble-1993" TOTAL_1="66" TOTAL_2="60" VAR="0.004469102178812923" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="37" EVENTS_2="40" I2="0.0" I2_Q="0.0" ID="CMP-005.10" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="10" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="67" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of adverse events (subject with any event)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1369176471459648" CI_START="0.6444485211859751" EFFECT_SIZE="0.8559701492537314" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.05572900762055646" LOG_CI_START="-0.19081176854763632" LOG_EFFECT_SIZE="-0.06754138046353993" ORDER="7292" O_E="0.0" SE="0.14481927231772074" STUDY_ID="STD-Gribble-1993" TOTAL_1="67" TOTAL_2="62" VAR="0.020972621634634155" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="41" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-005.11" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="11" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of need of antibiotics for urinary tract infection</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.974324159464516" CI_START="0.6188656769672952" EFFECT_SIZE="0.7765151515151515" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="48" LOG_CI_END="-0.011296528496021793" LOG_CI_START="-0.20840360313213183" LOG_EFFECT_SIZE="-0.10985006581407677" ORDER="7293" O_E="0.0" SE="0.11578167133700629" STUDY_ID="STD-Gribble-1993" TOTAL_1="66" TOTAL_2="60" VAR="0.013405395417590543" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="47" EVENTS_2="45" I2="0.0" I2_Q="0.0" ID="CMP-005.12" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="12" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="66" TOTAL_2="60" WEIGHT="0.0" Z="0.0">
<NAME>At least one episode of bacteriuria due to TMX-SMX-resistant organisms</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1735131517710489" CI_START="0.7682407800507601" EFFECT_SIZE="0.9494949494949495" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="45" LOG_CI_END="0.06948796117754909" LOG_CI_START="-0.11450264317325162" LOG_EFFECT_SIZE="-0.022507340997851254" ORDER="7294" O_E="0.0" SE="0.10807699176384054" STUDY_ID="STD-Gribble-1993" TOTAL_1="66" TOTAL_2="60" VAR="0.011680636148721255" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="33" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-005.13" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="13" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="NO" TOTAL_1="67" TOTAL_2="62" WEIGHT="0.0" Z="0.0">
<NAME>At least one time recovery of TMX-SMX-resistant gram-negative bacilli from weekly surveillance cultures</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7185144925964502" CI_START="0.8027157021599042" EFFECT_SIZE="1.17451205510907" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="26" LOG_CI_END="0.23515319898597448" LOG_CI_START="-0.09543824157698064" LOG_EFFECT_SIZE="0.06985747870449693" ORDER="7295" O_E="0.0" SE="0.19419104864070302" STUDY_ID="STD-Gribble-1993" TOTAL_1="67" TOTAL_2="62" VAR="0.03771016337217589" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2012-07-09 15:38:34 +0100" MODIFIED_BY="Charlotte Archibald" NO="6">
<NAME>Antibiotic for laboratory UTI versus antibiotic for clinical UTI</NAME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-01-31 11:51:36 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-01-31 11:51:36 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>PRISMA study flow diagram</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-01-31 11:09:39 +0000" MODIFIED_BY="[Empty name]"/>
<EXTENSIONS>
<EXTENSION ID="FLOW_1" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="1">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 reports of 8 studies included in quantitative synthesis (meta-analysis)&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;8 reports of 8 studies included in qualitative synthesis - one report &lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987a&quot; protected=&quot;true&quot;&gt;Mohler 1987a&lt;/a&gt; has 3 studies, one of which is included and two are excluded &lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987b&quot; protected=&quot;true&quot;&gt;Mohler 1987b&lt;/a&gt;&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;25 full-text articles assessed for eligibility - plus one report of 3 studies (&lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987a&quot; protected=&quot;true&quot;&gt;Mohler 1987a&lt;/a&gt;; &lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987b&quot; protected=&quot;true&quot;&gt;Mohler 1987b&lt;/a&gt;) one of the studies included and 2 excluded so same report appears in both lists.&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;624 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;624 records after duplicates removed&lt;/p&gt;" WIDTH="200">
<FLOWCHARTBOX TEXT="&lt;p&gt;621 records identified through searching the Specialised Register&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;3 additional records identified through searching reference lists&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;599 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;18 reports of 18 studies excluded, with reasons (one &lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987b&quot; protected=&quot;true&quot;&gt;Mohler 1987b&lt;/a&gt; reports 3 studies of which two are excluded and one &lt;a link_type=&quot;STUDY&quot; href=&quot;Mohler 1987a&quot; protected=&quot;true&quot;&gt;Mohler 1987a&lt;/a&gt; included)&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>